

SUPPLEMENTAL MATERIALS AND METHODS

Generation of AAVs

Human PNPLA3 wild type and I148M were synthesized and cloned into pUC57 shuttle plasmid (Genewiz LLC), MluI and Sall sites were introduced at 5' and 3' end respectively. The human PCSK9 wild type and I148M were subsequently subcloned into MluI and Sall sites of a pAAV cis plasmid that contains the liver-specific thyroxine binding globulin promoter. Luciferase driven by the same promoter was used as control. The recombinant AAV8 vectors were generated with the helper-free triple plasmid transfection method in HEK293 cells, and purified using double cesium chloride gradient centrifugation by the Viral Vector Core of University of Massachusetts Medical School. The titers were determined via digital-droplet PCR analysis.

Generation of siRNA

siRNA of placebo lipid nanoparticle (LNP) and si-hPNPLA3 were prepared as described by Gindy et al.(1). For placebo LNP, GS sequence is 5'-fluU;fluC;rG;omeA;fluC;fluC;omeG;omeA;fluU;omeA;fluU; omeA;omeA;rG; omeG;fluC;omeG;omeA;fluC;omeUs;omeU-3'. PS sequence is 5'-6amiL;dG;fluU;fluC; dG;fluC;fluC;fluU;fluU;dA;fluU;dA;fluU;fluC;dG;dG;fluU;fluC;dG;dA;omeUs;omeU;iB-3'. The core scrambled sequence is GTCGCCTTATATCGGTCGA. For si-hPNPLA3, GS sequence is 5'-fluU;fluU;fluA;fluC;omeA;fluU;omeA;omeA;omeG;omeA;fluC;omeA;fluU;fluU;omeA;fluU;fluC; fluC;fluU;omeUs;omeU-3'. PS sequence is 5'-iB;rA;rG;rG;rA;

omeU;rA;rA;omeU;rG;omeU;omeC;omeU; omeU;rA;omeU;rG;omeU;rA;rA;omeUs;
omeU;iB-3'. The core targeting sequence is AGGATAATGTCTTATGTAA. LNP platform
is 2'-O-me + 2'-F. siRNA stock reagents were diluted to desired concentration (0.175
mg/ml) by using Tris G diluent (10 mM tris buffer pH 7.5, 70 mM NaCl, 5% sucrose) before
treatment.

Isolation of mouse hepatocytes

To determine whether human PNPLA3 was expressed in mouse hepatocytes versus
hepatic stellate cells (HSCs), mice injected with PNPLA3^{I148M} were anesthetized with
isoflurane. Primary mouse hepatocytes were isolated via the ethylene glycol tetra-acetic
acid (EGTA)/collagenase perfusion technique, with microcannulation of the portal vein as
previously described(2). Hepatocytes were cultured in collagen-coated plates with
William's E containing penicillin (100 units/ml), insulin (1.5uM), dexamethasone (0.1 µM),
and thyroxine (1 µM). Primary mouse HSCs were isolated using gradient centrifugation
as previously described(3), and cultured with Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum, penicillin G (100 U/mL), and
streptomycin (100 µg/mL).

In vitro studies of effects of PNPLA3^{I148M} and STAT3 activation in hepatocytes on stellate cell activation:

Human HepG2 hepatoma cells which are known to carry the PNPLA3^{I148M} mutation were
incubated at 37°C for 3 days in 6-well plates containing 10% fetal bovine serum, 100
IU/ml penicillin, and 100 µg/ml streptomycin. To induce fibrosis in stellate cells, the

supernatants from Hep2G cultures were added to LX2 cells and incubated overnight in 6-well plates. Total RNA from cells were extracted using Trizol reagent to determine PNPLA3^{I148M} mRNA levels in HepG2 cells and procollagen mRNA expression in LX2 cells. For Stat3 inhibition experiments, HepG2 cells were treated with Stattic (a selective Stat3 inhibitor, Sigma Co.) at 1 μ M or 5 μ M for 2.5 h in normal glucose or high glucose DMEM. The media were replaced by fresh media for another 48 h. Supernatants were added to LX2 cells for overnight incubation, and HepG2 cells were collected and analyzed for Stat3, p-Stat3 and β -actin protein expression. After overnight incubation of LX2 cells in supernatant, total RNA of whole-cell lysates was extracted by using Trizol reagent to examine the effect of Stat3 inhibition on fibrosis markers.

mRNA extraction and real-time PCR

These were done as previously described (4). Liver tissues lysed in RLT lysis buffer (QIAGEN, 74104) were used for RNA isolation using RNEasy Mini Kit (QIAGEN, 74104) following the manufacturer's protocol. Total RNA yield, 260/280, and 260/230 ratios were determined using NanoDrop spectrophotometer (Thermo Scientific). Total RNA was reverse-transcribed into complementary DNA using reverse transcriptase and random primers (Invitrogen). Complementary DNA was quantified by real-time PCR using SYBR green fluorescence and TaqMan gene expression assays (Thermofisher) on a LightCycler 480 instrument (Roche Applied Science), relative to expression of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers and used were obtained from Invitrogen and Thermofisher.

Immunoblot Analysis

Briefly, 20 µg of protein were resolved by SDS-PAGE on a 4%-12% NuPAGE Novex Bis-Tris Mini Gel (Invitrogen), followed by transfer to nitrocellulose membrane and incubation with primary antibody and subsequently secondary antibody as per established protocols.

Metabolomic analyses

I. Metabolite extraction and LC-MS analysis: Two separate liquid chromatography (LC)-time of flight (ToF)-mass spectrometry (MS)-based platforms that analyzed methanol (Platform 1) and methanol/chloroform (Platform 2) extracts for lipid analyses were combined with a LC-single quadrupole-MS amino acid analysis (Platform 3) and a LC-ToF-MS platform for the analysis of polar metabolites in a methanol/H₂O extract (Platform 4)(5, 6). Identified metabolites in the methanol extract platform included fatty acids, acyl carnitines, bile acids, lysoglycerophospholipids, free sphingoid bases, N-acyl ethanolamines and oxidized fatty acids. The chloroform/methanol extract platform provided coverage over glycerolipids, cholesterol esters, sphingolipids and glycerophospholipids.

II. Metabolomics data analysis: Data were pre-processed using the TargetLynx application manager for MassLynx 4.1 software (Waters Corp., Milford, USA). Metabolites were identified prior to the analysis. Peak detection, noise reduction and data normalization were performed as previously described(7). The Shapiro-Wilk test for normality and Student's t-test for statistical significance determination between groups were performed.

Transcriptomic analysis

I. mRNA sequencing data Alignment and Annotations: This was done as described previously (8). mRNA sequence data were uploaded to a High Performance Computing system by PartekFlow® software (v7.0), adapter-trimmed and remapped to mouse genome, mm10 using STAR v2.5.2b aligner with default setting (phred: 20) for read mapping. mRNA reads were annotated to ensembl v87. Expression matrices were compared between mutant PNPLA3 versus LUC, and between mutant PNPLA3 versus wild-type PNPLA3. Statistical analyses were carried out using false discovery rate (FDR) correction through the Benjamini-Hochberg method. A default FDR <0.05 was considered statistically significant (8, 9), with a log₂-fold change more than 1 (Total count >100, FDR <0.05; low expressed: 100% of samples have ≥100 reads).

II. Biological Processes and Gene Network Visualization by MetaCore: This was also performed as described previously (8). Biological pathway interactions of mRNA expressions were analyzed using MetaCore pathway analysis of differentially expressed genes (Clarivate Analytics) with $p < 0.05$ and greater than two-fold change. We performed enrichment analysis on mutant PNPLA3 versus LUC, and on mutant PNPLA3 versus wild-type PNPLA3. Functional gene networks were built based on differentially regulated mRNA gene lists as input to generate disease biomarkers and Gene Ontology terms (8, 9).

III. Integrated pathway analysis:

A joint metabolome-transcriptome analysis was performed using the integrated pathway analysis module of Metaboanalyst 4.0. The updated KEGG pathways (October 2019) were used for annotation. The data were integrated by combining queries in which genes and metabolites were pooled in to a single query and used to perform enrichment

analysis. Additionally, weightage was given to the proportions of metabolites and genes at a pathway level to compute the read-out. Topology analyses using “degree centrality” i.e. the number of links that connect to a node was used to determine the impact of significantly altered pathways.

SUPPLEMENTAL REFERENCES

1. Gindy ME, DiFelice K, Kumar V, Prud'homme RK, Celano R, Haas RM, Smith JS, et al. Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery. *Langmuir* 2014;30:4613-4622.
2. Zhou H, Gurley EC, Jarujaron S, Ding H, Fang Y, Xu Z, Pandak WM, Jr., et al. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. *Am J Physiol Gastrointest Liver Physiol* 2006;291:G1071-1080.
3. Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. *Methods Mol Med* 2005;117:99-113.
4. Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. *Faseb J* 2016;30:4071-4082.
5. Barbier-Torres L, Delgado TC, Garcia-Rodriguez JL, Zubieta-Franco I, Fernandez-Ramos D, Buque X, Cano A, et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. *Oncotarget* 2015;6:2509-2523.
6. Barr J, Vazquez-Chantada M, Alonso C, Perez-Cormenzana M, Mayo R, Galan A, Caballeria J, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. *J Proteome Res* 2010;9:4501-4512.
7. Martinez-Arranz I, Mayo R, Perez-Cormenzana M, Minchole I, Salazar L, Alonso C, Mato JM. Enhancing metabolomics research through data mining. *J Proteomics* 2015;127:275-288.
8. Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. *J Hepatol* 2016;65:579-588.
9. Koduru SV, Leberfinger AN, Kawasawa YI, Mahajan M, Gusani NJ, Sanyal AJ, Ravnicek DJ. Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs. *Scientific reports* 2018;8:7967-7967.

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1: Generation of adeno associated virus (AAV). (A-C). Human PNPLA3 wild type and mutant I148M were synthesized and cloned into pUC57 shuttle plasmid as described in the Methods section. Luciferase (LUC) driven by the same promoter was used as control. The recombinant AAV8 vectors containing LUC (A), PNPLA3^{WT} (B) or PNPLA3^{I148M} (C) were generated with the helper-free triple plasmid transfection method in HEK293 cells and purified by gradient centrifugation.

Supplemental Figure 2: PNPLA3^{I148M} expression does not alter liver histology under conditions of chow diet. (A) Liver tissue collected at the time of sacrifice were sectioned for histological analysis; representative Hematoxylin and eosin (H&E) stained sections of liver tissue for mice on CDNW are shown. All mice on chow diet showed similar liver histology, with histological scores of 0 for all groups (data not shown). (B) Similarly, mice on chow diet did not develop fibrosis irrespective of type of AAV construct.


Supplemental Figure 3: PNPLA3 overexpression leads to PUFA depletion with minimal effect on de novo lipogenesis. (A) Similar to PNPLA3^{I148M}, PNPLA3^{WT} (versus luc) led to PUFA depletion under conditions of chow diet (top panel) and western diet (middle panel). PNPLA3^{I148M} conferred a greater depletion of PUFA when compared to PNPLA3^{WT} (bottom panel). (B) Based on integrated pathway analyses, PNPLA3^{I148M} did not significantly alter de novo lipogenesis pathways. (C) Western blot analysis showed a mild increase in hepatic SREBP1, FASN and ACC protein expression. (D) The mRNA

levels of CGI58, which has been linked to PNPLA3 TAG hydrolytic function was induced by PNPLA3^{I148M} but did not decrease significantly after silencing PNPLA3.



Supplemental Figure 4. PNPLA3^{I148M} under WDSW diet conditions activated innate immune system and inflammatory response pathways. (A) Top scored maps (those with the lowest p-value) based on the enrichment distribution were determined. These maps were primarily involved in immune response, including IL-6 induced innate immune response (B) and renal tubulointerstitial injury (C). Upward (red) thermometers indicate up-regulated signals and down-ward (blue) thermometers indicate down-regulated gene expression.

Supplemental Figure 5: PNPLA3^{I148M} under WDSW diet conditions induced gene ontology processes and networks involved in immune response. (A-B) The top 10 upregulated gene ontology processes (A) and process networks (B) were determined based on transcriptomic analysis of PNPLA3^{I148M} versus luc under conditions of WDSW. (C-D) The top scored networks included the STAT1-CD14 network (C) and MHC class II immune response network (D), with $p = 5.46 \times 10^{-54}$ and 1.85×10^{-39} , respectively. Up-regulated genes are marked with red circles; down-regulated genes are indicated by blue circles.

Supplementary Figure 1




Supplementary Figure 2




Supplementary Figure 3

A


PNPLA3^{WT} vs LUC on CDNW



PNPLA3^{WT} vs LUC on WDSW






PNPLA3^{I148M} vs PNPLA3^{WT} on WDSW




B PNPLA3^{WT} vs LUC on WDSW

| Pathway | # targets | # hits | P value | FDR | Impact |
|--------------------------|-----------|--------|---------|-------|--------|
| FA Biosynthesis | 102 | 2 | 0.9 | 1 | 0.05 |
| FA Degradation | 129 | 3 | 0.9 | 1 | 0.07 |
| FA Elongation | 75 | 6 | 0.8 | 1 | 0.1 |
| Unsaturated FA synthesis | 81 | 15 | 8.7E-4 | 0.004 | 3 |

C




D




Supplementary Figure 4

A Maps: PNPLA3^{I148M} vs LUC on WDSW




B Map of Immune response_IL-6-induced acute-phase response in hepatocytes




Supplementary Figure 4 continued

C Map of Renal tubulointerstitial injury




Supplementary Figure 5


A Processes: PNPLA3^{I148M} vs LUC on WDSW




B Networks: PNPLA3^{I148M} vs LUC on WDSW



C STAT1-CD14 network activation



D Immune response: MHC Class II network activation



Supplemental Table 1: PNPLA3^{I148M} vs Luc on CDNW

| | Pathway | Total number of targets | Expected number of targets | Number of Hits | Raw p-value | Log10(p-value) | Holm adjust | FDR | Impact |
|----|---|-------------------------|----------------------------|----------------|-------------|----------------|-------------|----------|----------|
| 1 | Central carbon metabolism in cancer | 104 | 1.0256 | 19 | 2.61E-19 | 18.583 | 8.54E-17 | 8.54E-17 | 0 |
| 2 | Aminoacyl-tRNA biosynthesis | 118 | 1.1637 | 18 | 7.17E-17 | 16.144 | 2.34E-14 | 9.63E-15 | 0.18557 |
| 3 | ABC transporters | 186 | 1.8343 | 21 | 8.84E-17 | 16.054 | 2.87E-14 | 9.63E-15 | 0 |
| 4 | Protein digestion and absorption | 141 | 1.3905 | 18 | 1.86E-15 | 14.731 | 6.02E-13 | 1.52E-13 | 0 |
| 5 | Mineral absorption | 81 | 0.79879 | 13 | 9.14E-13 | 12.039 | 2.95E-10 | 4.98E-11 | 0 |
| 6 | Biosynthesis of unsaturated fatty acids | 81 | 0.79879 | 13 | 9.14E-13 | 12.039 | 2.95E-10 | 4.98E-11 | 0.075758 |
| 7 | Primary bile acid biosynthesis | 63 | 0.62128 | 8 | 1.74E-07 | 6.7599 | 5.58E-05 | 8.12E-06 | 0.15957 |
| 8 | Alanine, aspartate and glutamate metabolism | 66 | 0.65087 | 8 | 2.52E-07 | 6.5994 | 8.05E-05 | 1.03E-05 | 0.57377 |
| 9 | Vitamin digestion and absorption | 63 | 0.62128 | 7 | 2.66E-06 | 5.5749 | 0.000849 | 8.44E-05 | 0 |
| 10 | Glycine, serine and threonine metabolism | 90 | 0.88754 | 8 | 2.79E-06 | 5.5546 | 0.000887 | 8.44E-05 | 0.46591 |
| 11 | Purine metabolism | 231 | 2.278 | 12 | 2.84E-06 | 5.5469 | 0.0009 | 8.44E-05 | 0.39216 |
| 12 | Arginine biosynthesis | 42 | 0.41419 | 6 | 3.18E-06 | 5.4974 | 0.001005 | 8.67E-05 | 0.4 |
| 13 | Linoleic acid metabolism | 78 | 0.76921 | 7 | 1.13E-05 | 4.9488 | 0.003544 | 0.000283 | 0.31707 |
| 14 | Taurine and hypotaurine metabolism | 33 | 0.32543 | 5 | 1.63E-05 | 4.7874 | 0.005123 | 0.000381 | 0.27586 |
| 15 | Cholesterol metabolism | 59 | 0.58183 | 6 | 2.38E-05 | 4.6227 | 0.007462 | 0.00052 | 0 |
| 16 | Aldosterone synthesis and secretion | 123 | 1.213 | 8 | 2.83E-05 | 4.5485 | 0.008823 | 0.000578 | 0 |
| 17 | Nicotinate and nicotinamide metabolism | 98 | 0.96644 | 7 | 5.01E-05 | 4.3003 | 0.015578 | 0.000963 | 0.2439 |
| 18 | Phenylalanine, tyrosine and tryptophan biosynthesis | 43 | 0.42405 | 5 | 6.12E-05 | 4.2135 | 0.01896 | 0.001111 | 0.29268 |
| 19 | Leishmaniasis | 74 | 0.72976 | 6 | 8.69E-05 | 4.0609 | 0.026856 | 0.001496 | 0.13208 |
| 20 | Valine, leucine and isoleucine biosynthesis | 27 | 0.26626 | 4 | 0.000132 | 3.8781 | 0.040781 | 0.002152 | 0.19231 |
| 21 | Cysteine and methionine metabolism | 115 | 1.1341 | 7 | 0.000138 | 3.8594 | 0.042432 | 0.002152 | 0.13592 |
| 22 | Antifolate resistance | 58 | 0.57197 | 5 | 0.000259 | 3.587 | 0.079194 | 0.003847 | 0 |
| 23 | beta-Alanine metabolism | 64 | 0.63114 | 5 | 0.000411 | 3.3863 | 0.12532 | 0.005842 | 0.11111 |
| 24 | Glutathione metabolism | 103 | 1.0157 | 6 | 0.000532 | 3.274 | 0.16175 | 0.00725 | 0.31884 |
| 25 | Ferroptosis | 72 | 0.71004 | 5 | 0.000708 | 3.1498 | 0.2146 | 0.00911 | 0.027027 |
| 26 | Bile secretion | 246 | 2.426 | 9 | 0.000724 | 3.1401 | 0.21875 | 0.00911 | 0.014085 |
| 27 | Sulfur metabolism | 44 | 0.43391 | 4 | 0.0009 | 3.0457 | 0.27094 | 0.010902 | 0 |
| 28 | Fatty acid biosynthesis | 77 | 0.75934 | 5 | 0.000962 | 3.0169 | 0.28854 | 0.011233 | 0.017442 |
| 29 | Pantothenate and CoA biosynthesis | 46 | 0.45363 | 4 | 0.001066 | 2.9723 | 0.31867 | 0.012018 | 0.16667 |
| 30 | Phenylalanine metabolism | 83 | 0.81851 | 5 | 0.001349 | 2.8701 | 0.40192 | 0.014701 | 0.12329 |
| 31 | Glyoxylate and dicarboxylate metabolism | 93 | 0.91713 | 5 | 0.002233 | 2.6511 | 0.66326 | 0.023557 | 0.079545 |
| 32 | Asthma | 29 | 0.28599 | 3 | 0.002834 | 2.5476 | 0.83887 | 0.028391 | 0 |
| 33 | Inflammatory bowel disease (IBD) | 60 | 0.5917 | 4 | 0.002865 | 2.5429 | 0.84521 | 0.028391 | 0.032258 |
| 34 | Butanoate metabolism | 69 | 0.68045 | 4 | 0.004747 | 2.3236 | 1 | 0.044737 | 0.090909 |
| 35 | Toxoplasmosis | 111 | 1.0946 | 5 | 0.004788 | 2.3198 | 1 | 0.044737 | 0.11111 |
| 36 | Regulation of lipolysis in adipocytes | 70 | 0.69031 | 4 | 0.004997 | 2.3013 | 1 | 0.045385 | 0.033333 |
| 37 | Sphingolipid metabolism | 73 | 0.7199 | 4 | 0.005799 | 2.2366 | 1 | 0.051251 | 0.36066 |
| 38 | Proximal tubule bicarbonate reclamation | 39 | 0.3846 | 3 | 0.0066 | 2.1805 | 1 | 0.056791 | 0 |
| 39 | Taste transduction | 121 | 1.1933 | 5 | 0.006873 | 2.1628 | 1 | 0.05763 | 0.11429 |
| 40 | Pyrimidine metabolism | 123 | 1.213 | 5 | 0.007356 | 2.1334 | 1 | 0.060136 | 0.18605 |
| 41 | Ovarian steroidogenesis | 81 | 0.79879 | 4 | 0.008348 | 2.0784 | 1 | 0.066579 | 0 |
| 42 | Intestinal immune network for IgA production | 44 | 0.43391 | 3 | 0.00923 | 2.0348 | 1 | 0.071859 | 0 |
| 43 | Thiamine metabolism | 46 | 0.45363 | 3 | 0.010429 | 1.9817 | 1 | 0.079313 | 0 |
| 44 | D-Glutamine and D-glutamate metabolism | 17 | 0.16765 | 2 | 0.011906 | 1.9242 | 1 | 0.087095 | 0.25 |
| 45 | Th1 and Th2 cell differentiation | 90 | 0.88754 | 4 | 0.011986 | 1.9213 | 1 | 0.087095 | 0.070423 |
| 46 | Antigen processing and presentation | 91 | 0.89741 | 4 | 0.012443 | 1.9051 | 1 | 0.088456 | 0.36842 |
| 47 | Thyroid hormone synthesis | 94 | 0.92699 | 4 | 0.013883 | 1.8575 | 1 | 0.096592 | 0 |
| 48 | Fat digestion and absorption | 53 | 0.52267 | 3 | 0.015316 | 1.8149 | 1 | 0.10434 | 0 |
| 49 | Oxidative phosphorylation | 149 | 1.4694 | 5 | 0.015931 | 1.7978 | 1 | 0.10439 | 0 |
| 50 | GABAergic synapse | 98 | 0.96644 | 4 | 0.015962 | 1.7969 | 1 | 0.10439 | 0.071429 |
| 51 | Amino sugar and nucleotide sugar metabolism | 157 | 1.5483 | 5 | 0.019527 | 1.7094 | 1 | 0.1252 | 0.074534 |
| 52 | Th17 cell differentiation | 106 | 1.0453 | 4 | 0.020682 | 1.6844 | 1 | 0.13006 | 0.028571 |
| 53 | Arachidonic acid metabolism | 164 | 1.6173 | 5 | 0.02308 | 1.6368 | 1 | 0.1424 | 0.15385 |
| 54 | Retrograde endocannabinoid signaling | 167 | 1.6469 | 5 | 0.024723 | 1.6069 | 1 | 0.14971 | 0.02381 |
| 55 | Allograft rejection | 64 | 0.63114 | 3 | 0.025204 | 1.5985 | 1 | 0.14985 | 0 |
| 56 | Lysine degradation | 115 | 1.1341 | 4 | 0.026923 | 1.5699 | 1 | 0.15721 | 0.051948 |
| 57 | Graft-versus-host disease | 67 | 0.66073 | 3 | 0.028374 | 1.5471 | 1 | 0.16278 | 0 |
| 58 | Pyruvate metabolism | 69 | 0.68045 | 3 | 0.0306 | 1.5143 | 1 | 0.16536 | 0.075472 |
| 59 | alpha-Linolenic acid metabolism | 69 | 0.68045 | 3 | 0.0306 | 1.5143 | 1 | 0.16536 | 0.11538 |
| 60 | Riboflavin metabolism | 28 | 0.27612 | 2 | 0.030848 | 1.5108 | 1 | 0.16536 | 0.20833 |
| 61 | One carbon pool by folate | 28 | 0.27612 | 2 | 0.030848 | 1.5108 | 1 | 0.16536 | 0.23333 |
| 62 | Starch and sucrose metabolism | 70 | 0.69031 | 3 | 0.031746 | 1.4983 | 1 | 0.16743 | 0.041096 |
| 63 | Histidine metabolism | 71 | 0.70017 | 3 | 0.032915 | 1.4826 | 1 | 0.17084 | 0.12903 |
| 64 | Type 1 diabetes mellitus | 73 | 0.7199 | 3 | 0.035319 | 1.452 | 1 | 0.18046 | 0 |
| 65 | Arginine and proline metabolism | 128 | 1.2623 | 4 | 0.037736 | 1.4232 | 1 | 0.18984 | 0.12821 |
| 66 | Galactose metabolism | 78 | 0.76921 | 3 | 0.041714 | 1.3797 | 1 | 0.20668 | 0.22535 |
| 67 | Tuberculosis | 195 | 1.923 | 5 | 0.04372 | 1.3593 | 1 | 0.21338 | 0.073529 |
| 68 | Neuroactive ligand-receptor interaction | 402 | 3.9644 | 8 | 0.04523 | 1.3446 | 1 | 0.2175 | 0.0625 |
| 69 | Autoimmune thyroid disease | 82 | 0.80865 | 3 | 0.047222 | 1.3259 | 1 | 0.22379 | 0 |
| 70 | Sphingolipid signaling pathway | 139 | 1.3708 | 4 | 0.048578 | 1.3136 | 1 | 0.22508 | 0.060976 |

| | | | | | | | | | |
|-----|--|-----|---------|---|----------|---------|---|---------|----------|
| 71 | Nitrogen metabolism | 36 | 0.35502 | 2 | 0.048871 | 1.311 | 1 | 0.22508 | 0.065217 |
| 72 | Viral myocarditis | 88 | 0.86782 | 3 | 0.056117 | 1.2509 | 1 | 0.25145 | 0 |
| 73 | Synaptic vesicle cycle | 89 | 0.87768 | 3 | 0.057672 | 1.239 | 1 | 0.25145 | 0 |
| 74 | Rheumatoid arthritis | 89 | 0.87768 | 3 | 0.057672 | 1.239 | 1 | 0.25145 | 0 |
| 75 | Fructose and mannose metabolism | 89 | 0.87768 | 3 | 0.057672 | 1.239 | 1 | 0.25145 | 0.14865 |
| 76 | AMPK signaling pathway | 149 | 1.4694 | 4 | 0.059778 | 1.2235 | 1 | 0.2572 | 0.010638 |
| 77 | Renin secretion | 93 | 0.91713 | 3 | 0.064095 | 1.1932 | 1 | 0.27219 | 0.017857 |
| 78 | Hematopoietic cell lineage | 94 | 0.92699 | 3 | 0.06575 | 1.1821 | 1 | 0.27564 | 0 |
| 79 | Parkinson disease | 157 | 1.5483 | 4 | 0.069645 | 1.1571 | 1 | 0.28828 | 0.014925 |
| 80 | Valine, leucine and isoleucine degradation | 98 | 0.96644 | 3 | 0.072566 | 1.1393 | 1 | 0.29661 | 0.072917 |
| 81 | African trypanosomiasis | 46 | 0.45363 | 2 | 0.075392 | 1.1227 | 1 | 0.30436 | 0 |
| 82 | Nicotine addiction | 47 | 0.4635 | 2 | 0.078251 | 1.1065 | 1 | 0.31205 | 0.078125 |
| 83 | Morphine addiction | 103 | 1.0157 | 3 | 0.08151 | 1.0888 | 1 | 0.32113 | 0.07 |
| 84 | Influenza A | 169 | 1.6666 | 4 | 0.085914 | 1.0659 | 1 | 0.33445 | 0.044248 |
| 85 | cAMP signaling pathway | 240 | 2.3668 | 5 | 0.088733 | 1.0519 | 1 | 0.33762 | 0.040984 |
| 86 | Cell adhesion molecules (CAMs) | 171 | 1.6863 | 4 | 0.088792 | 1.0516 | 1 | 0.33762 | 0.007663 |
| 87 | Citrate cycle (TCA cycle) | 52 | 0.5128 | 2 | 0.093034 | 1.0314 | 1 | 0.34968 | 0.18182 |
| 88 | Cocaine addiction | 56 | 0.55225 | 2 | 0.10539 | 0.97719 | 1 | 0.39162 | 0.024691 |
| 89 | Tyrosine metabolism | 118 | 1.1637 | 3 | 0.11097 | 0.9548 | 1 | 0.40627 | 0.08871 |
| 90 | Necroptosis | 186 | 1.8343 | 4 | 0.11182 | 0.95149 | 1 | 0.40627 | 0.042553 |
| 91 | Staphylococcus aureus infection | 123 | 1.213 | 3 | 0.12159 | 0.91512 | 1 | 0.4369 | 0 |
| 92 | Phosphonate and phosphinate metabolism | 63 | 0.62128 | 2 | 0.12798 | 0.89284 | 1 | 0.4549 | 0 |
| 93 | Glucagon signaling pathway | 130 | 1.282 | 3 | 0.13704 | 0.86314 | 1 | 0.47674 | 0 |
| 94 | Tryptophan metabolism | 130 | 1.282 | 3 | 0.13704 | 0.86314 | 1 | 0.47674 | 0.088 |
| 95 | Pentose phosphate pathway | 67 | 0.66073 | 2 | 0.14136 | 0.84967 | 1 | 0.48658 | 0.2381 |
| 96 | FoxO signaling pathway | 136 | 1.3412 | 3 | 0.1508 | 0.82159 | 1 | 0.51101 | 0.035714 |
| 97 | Long-term depression | 70 | 0.69031 | 2 | 0.15158 | 0.81935 | 1 | 0.51101 | 0.1087 |
| 98 | Sulfur relay system | 19 | 0.18737 | 1 | 0.17175 | 0.7651 | 1 | 0.56885 | 0 |
| 99 | Systemic lupus erythematosus | 145 | 1.4299 | 3 | 0.17222 | 0.76392 | 1 | 0.56885 | 0 |
| 100 | Steroid biosynthesis | 77 | 0.75934 | 2 | 0.17596 | 0.75459 | 1 | 0.57538 | 0.091837 |
| 101 | Amphetamine addiction | 78 | 0.76921 | 2 | 0.17949 | 0.74596 | 1 | 0.58112 | 0.038462 |
| 102 | Glycerophospholipid metabolism | 149 | 1.4694 | 3 | 0.18201 | 0.73991 | 1 | 0.58349 | 0.19048 |
| 103 | Cortisol synthesis and secretion | 81 | 0.79879 | 2 | 0.19015 | 0.7209 | 1 | 0.60369 | 0 |
| 104 | Epstein-Barr virus infection | 232 | 2.2879 | 4 | 0.19604 | 0.70765 | 1 | 0.61447 | 0.055172 |
| 105 | Prolactin signaling pathway | 83 | 0.81851 | 2 | 0.19731 | 0.70486 | 1 | 0.61447 | 0.25758 |
| 106 | Neomycin, kanamycin and gentamicin biosynthesis | 86 | 0.8481 | 2 | 0.2081 | 0.68173 | 1 | 0.64197 | 0 |
| 107 | Pentose and glucuronate interconversions | 89 | 0.87768 | 2 | 0.21896 | 0.65964 | 1 | 0.66915 | 0.10294 |
| 108 | Caffeine metabolism | 28 | 0.27612 | 1 | 0.24256 | 0.61518 | 1 | 0.73441 | 0 |
| 109 | Longevity regulating pathway | 98 | 0.96644 | 2 | 0.25176 | 0.59901 | 1 | 0.75246 | 0.055556 |
| 110 | Glycerolipid metabolism | 99 | 0.9763 | 2 | 0.25542 | 0.59274 | 1 | 0.75246 | 0.051724 |
| 111 | Toll-like receptor signaling pathway | 99 | 0.9763 | 2 | 0.25542 | 0.59274 | 1 | 0.75246 | 0.072289 |
| 112 | Phagosome | 181 | 1.785 | 3 | 0.2646 | 0.57741 | 1 | 0.76628 | 0 |
| 113 | Biotin metabolism | 31 | 0.30571 | 1 | 0.2648 | 0.57708 | 1 | 0.76628 | 0.026316 |
| 114 | Porphyrin and chlorophyll metabolism | 183 | 1.8047 | 3 | 0.26994 | 0.56873 | 1 | 0.7743 | 0.012346 |
| 115 | Choline metabolism in cancer | 109 | 1.0749 | 2 | 0.29202 | 0.53459 | 1 | 0.82636 | 0 |
| 116 | Autophagy - other | 35 | 0.34516 | 1 | 0.29345 | 0.53247 | 1 | 0.82636 | 0.027778 |
| 117 | AGE-RAGE signaling pathway in diabetic complications | 110 | 1.0848 | 2 | 0.29567 | 0.52919 | 1 | 0.82636 | 0.059701 |
| 118 | Vitamin B6 metabolism | 37 | 0.36488 | 1 | 0.30736 | 0.51236 | 1 | 0.85174 | 0.025641 |
| 119 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 39 | 0.3846 | 1 | 0.32099 | 0.4935 | 1 | 0.88206 | 0.093023 |
| 120 | Glutamatergic synapse | 121 | 1.1933 | 2 | 0.33561 | 0.47416 | 1 | 0.91454 | 0.18571 |
| 121 | Alcoholism | 211 | 2.0808 | 3 | 0.34545 | 0.46161 | 1 | 0.93358 | 0.01 |
| 122 | Selenocompound metabolism | 44 | 0.43391 | 1 | 0.35393 | 0.45108 | 1 | 0.94865 | 0.02381 |
| 123 | Lysosome | 128 | 1.2623 | 2 | 0.3607 | 0.44285 | 1 | 0.95894 | 0 |
| 124 | Insulin resistance | 130 | 1.282 | 2 | 0.36781 | 0.43437 | 1 | 0.96995 | 0.022059 |
| 125 | Platelet activation | 139 | 1.3708 | 2 | 0.3994 | 0.39859 | 1 | 1 | 0.046512 |
| 126 | Autophagy - animal | 144 | 1.4201 | 2 | 0.41664 | 0.38024 | 1 | 1 | 0.016667 |
| 127 | Herpes simplex virus 1 infection | 439 | 4.3292 | 5 | 0.43666 | 0.35986 | 1 | 1 | 0.098485 |
| 128 | Drug metabolism - other enzymes | 151 | 1.4891 | 2 | 0.44035 | 0.3562 | 1 | 1 | 0 |
| 129 | Human T-cell leukemia virus 1 infection | 251 | 2.4753 | 3 | 0.4517 | 0.34515 | 1 | 1 | 0.007692 |
| 130 | Thermogenesis | 253 | 2.495 | 3 | 0.45685 | 0.34022 | 1 | 1 | 0 |
| 131 | Vascular smooth muscle contraction | 156 | 1.5384 | 2 | 0.45697 | 0.34011 | 1 | 1 | 0.028169 |
| 132 | Amyotrophic lateral sclerosis (ALS) | 62 | 0.61142 | 1 | 0.45991 | 0.33733 | 1 | 1 | 0.018519 |
| 133 | mTOR signaling pathway | 158 | 1.5581 | 2 | 0.46354 | 0.33391 | 1 | 1 | 0.02381 |
| 134 | Basal cell carcinoma | 64 | 0.63114 | 1 | 0.47057 | 0.32738 | 1 | 1 | 0 |
| 135 | Inflammatory mediator regulation of TRP channels | 162 | 1.5976 | 2 | 0.47654 | 0.3219 | 1 | 1 | 0.044944 |
| 136 | Fatty acid elongation | 69 | 0.68045 | 1 | 0.4963 | 0.30426 | 1 | 1 | 0.012658 |
| 137 | Renal cell carcinoma | 71 | 0.70017 | 1 | 0.50624 | 0.29564 | 1 | 1 | 0.017544 |
| 138 | Cushing syndrome | 172 | 1.6962 | 2 | 0.50819 | 0.29398 | 1 | 1 | 0 |
| 139 | GnRH secretion | 72 | 0.71004 | 1 | 0.51114 | 0.29146 | 1 | 1 | 0 |
| 140 | Ether lipid metabolism | 72 | 0.71004 | 1 | 0.51114 | 0.29146 | 1 | 1 | 0.093023 |
| 141 | Serotonergic synapse | 173 | 1.7061 | 2 | 0.51128 | 0.29134 | 1 | 1 | 0 |
| 142 | Long-term potentiation | 74 | 0.72976 | 1 | 0.52079 | 0.28334 | 1 | 1 | 0.096774 |
| 143 | Ascorbate and aldarate metabolism | 76 | 0.74948 | 1 | 0.53025 | 0.27552 | 1 | 1 | 0.018182 |

| | | | | | | | | | |
|-----|---|------|---------|---|---------|----------|---|---|----------|
| 144 | Fc epsilon RI signaling pathway | 78 | 0.76921 | 1 | 0.53953 | 0.26798 | 1 | 1 | 0.02 |
| 145 | Adipocytokine signaling pathway | 78 | 0.76921 | 1 | 0.53953 | 0.26798 | 1 | 1 | 0.023256 |
| 146 | Pancreatic cancer | 78 | 0.76921 | 1 | 0.53953 | 0.26798 | 1 | 1 | 0.035088 |
| 147 | cGMP-PKG signaling pathway | 183 | 1.8047 | 2 | 0.54155 | 0.26636 | 1 | 1 | 0.012195 |
| 148 | Propanoate metabolism | 81 | 0.79879 | 1 | 0.55311 | 0.25719 | 1 | 1 | 0.027778 |
| 149 | Folate biosynthesis | 83 | 0.81851 | 1 | 0.56194 | 0.25031 | 1 | 1 | 0.033708 |
| 150 | EGFR tyrosine kinase inhibitor resistance | 83 | 0.81851 | 1 | 0.56194 | 0.25031 | 1 | 1 | 0.090909 |
| 151 | Pertussis | 86 | 0.8481 | 1 | 0.57486 | 0.24044 | 1 | 1 | 0 |
| 152 | Chemokine signaling pathway | 203 | 2.0019 | 2 | 0.59814 | 0.2232 | 1 | 1 | 0.03125 |
| 153 | PPAR signaling pathway | 92 | 0.90727 | 1 | 0.59958 | 0.22215 | 1 | 1 | 0.016949 |
| 154 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 92 | 0.90727 | 1 | 0.59958 | 0.22215 | 1 | 1 | 0.025 |
| 155 | GnRH signaling pathway | 96 | 0.94671 | 1 | 0.61526 | 0.21094 | 1 | 1 | 0 |
| 156 | Gap junction | 97 | 0.95658 | 1 | 0.61909 | 0.20825 | 1 | 1 | 0.019231 |
| 157 | Glycolysis or Gluconeogenesis | 97 | 0.95658 | 1 | 0.61909 | 0.20825 | 1 | 1 | 0.092308 |
| 158 | Fc gamma R-mediated phagocytosis | 98 | 0.96644 | 1 | 0.62288 | 0.2056 | 1 | 1 | 0.037037 |
| 159 | Fatty acid degradation | 100 | 0.98616 | 1 | 0.63034 | 0.20043 | 1 | 1 | 0.016807 |
| 160 | Viral protein interaction with cytokine and cytokine receptor | 103 | 1.0157 | 1 | 0.64126 | 0.19297 | 1 | 1 | 0.006849 |
| 161 | Ubiquinone and other terpenoid-quinone biosynthesis | 103 | 1.0157 | 1 | 0.64126 | 0.19297 | 1 | 1 | 0.011628 |
| 162 | Kaposi sarcoma-associated herpesvirus infection | 221 | 2.1794 | 2 | 0.6445 | 0.19078 | 1 | 1 | 0.022901 |
| 163 | Melanogenesis | 106 | 1.0453 | 1 | 0.65186 | 0.18585 | 1 | 1 | 0.022727 |
| 164 | Circadian entrainment | 107 | 1.0552 | 1 | 0.65532 | 0.18355 | 1 | 1 | 0.068966 |
| 165 | Parathyroid hormone synthesis, secretion and action | 117 | 1.1538 | 1 | 0.68813 | 0.16233 | 1 | 1 | 0 |
| 166 | Amoebiasis | 120 | 1.1834 | 1 | 0.69736 | 0.15655 | 1 | 1 | 0 |
| 167 | Growth hormone synthesis, secretion and action | 120 | 1.1834 | 1 | 0.69736 | 0.15655 | 1 | 1 | 0.11111 |
| 168 | C-type lectin receptor signaling pathway | 124 | 1.2228 | 1 | 0.70924 | 0.14921 | 1 | 1 | 0.021053 |
| 169 | Neurotrophin signaling pathway | 126 | 1.2426 | 1 | 0.715 | 0.14569 | 1 | 1 | 0 |
| 170 | Thyroid hormone signaling pathway | 129 | 1.2721 | 1 | 0.72344 | 0.1406 | 1 | 1 | 0.009434 |
| 171 | Osteoclast differentiation | 131 | 1.2919 | 1 | 0.72893 | 0.13732 | 1 | 1 | 0.052632 |
| 172 | Estrogen signaling pathway | 142 | 1.4003 | 1 | 0.75723 | 0.12077 | 1 | 1 | 0.012987 |
| 173 | Measles | 145 | 1.4299 | 1 | 0.76442 | 0.11667 | 1 | 1 | 0.033708 |
| 174 | Dopaminergic synapse | 146 | 1.4398 | 1 | 0.76677 | 0.11533 | 1 | 1 | 0 |
| 175 | Phospholipase D signaling pathway | 159 | 1.568 | 1 | 0.79531 | 0.099466 | 1 | 1 | 0.014493 |
| 176 | Hepatitis C | 162 | 1.5976 | 1 | 0.80138 | 0.096161 | 1 | 1 | 0.051546 |
| 177 | Hepatitis B | 163 | 1.6074 | 1 | 0.80337 | 0.095086 | 1 | 1 | 0.022222 |
| 178 | Oxytocin signaling pathway | 165 | 1.6272 | 1 | 0.80728 | 0.092976 | 1 | 1 | 0.013158 |
| 179 | JAK-STAT signaling pathway | 165 | 1.6272 | 1 | 0.80728 | 0.092976 | 1 | 1 | 1.0556 |
| 180 | RNA transport | 169 | 1.6666 | 1 | 0.81487 | 0.08891 | 1 | 1 | 0 |
| 181 | Steroid hormone biosynthesis | 188 | 1.854 | 1 | 0.84708 | 0.072075 | 1 | 1 | 0.015228 |
| 182 | Huntington disease | 196 | 1.9329 | 1 | 0.85892 | 0.066048 | 1 | 1 | 0.014706 |
| 183 | Calcium signaling pathway | 202 | 1.992 | 1 | 0.8672 | 0.061883 | 1 | 1 | 0.014925 |
| 184 | NOD-like receptor signaling pathway | 215 | 2.1202 | 1 | 0.88351 | 0.053786 | 1 | 1 | 0.012121 |
| 185 | Rap1 signaling pathway | 219 | 2.1597 | 1 | 0.88812 | 0.051527 | 1 | 1 | 0.010638 |
| 186 | Ras signaling pathway | 239 | 2.3569 | 1 | 0.90859 | 0.041632 | 1 | 1 | 0.010417 |
| 187 | Pathways in cancer | 570 | 5.6211 | 3 | 0.92473 | 0.033984 | 1 | 1 | 0.015576 |
| 188 | Endocytosis | 275 | 2.7119 | 1 | 0.93652 | 0.028484 | 1 | 1 | 0 |
| 189 | Cytokine-cytokine receptor interaction | 296 | 2.919 | 1 | 0.94871 | 0.022869 | 1 | 1 | 0.0025 |
| 190 | PI3K-Akt signaling pathway | 359 | 3.5403 | 1 | 0.973 | 0.011886 | 1 | 1 | 0.009901 |
| 191 | Human papillomavirus infection | 364 | 3.5896 | 1 | 0.97435 | 0.011286 | 1 | 1 | 0.04375 |
| 192 | Olfactory transduction | 1141 | 11.252 | 1 | 0.99999 | 3.00E-06 | 1 | 1 | 0 |

Supplemental Table 2: Luc on WDSW vs Luc on CDNW

| | Pathway | Total number of targets | Expected number of targets | Number of Hits | Raw p-value | Log10(p-value) | Holm adjust | FDR | Impact |
|----|--|-------------------------|----------------------------|----------------|-------------|----------------|-------------|----------|----------|
| 1 | Aminoacyl-tRNA biosynthesis | 74 | 5.4608 | 18 | 3.36E-06 | 5.4742 | 0.000282 | 0.000282 | 0.26027 |
| 2 | Valine, leucine and isoleucine biosynthesis | 12 | 0.88553 | 6 | 9.44E-05 | 4.0251 | 0.007834 | 0.003964 | 0.63636 |
| 3 | Alanine, aspartate and glutamate metabolism | 61 | 4.5015 | 13 | 0.00035 | 3.4554 | 0.028738 | 0.009813 | 0.78333 |
| 4 | Biosynthesis of unsaturated fatty acids | 47 | 3.4683 | 10 | 0.001737 | 2.7602 | 0.14069 | 0.036475 | 0.21739 |
| 5 | Arginine biosynthesis | 27 | 1.9925 | 7 | 0.002646 | 2.5775 | 0.21164 | 0.044445 | 0.61538 |
| 6 | Phenylalanine metabolism | 24 | 1.7711 | 6 | 0.006504 | 2.1868 | 0.5138 | 0.091054 | 0.73913 |
| 7 | Sphingolipid metabolism | 58 | 4.2801 | 10 | 0.008592 | 2.0659 | 0.67014 | 0.1031 | 0.84211 |
| 8 | Cysteine and methionine metabolism | 71 | 5.2394 | 11 | 0.013288 | 1.8765 | 1 | 0.13953 | 0.62857 |
| 9 | alpha-Linolenic acid metabolism | 22 | 1.6235 | 5 | 0.019398 | 1.7123 | 1 | 0.18104 | 0.66667 |
| 10 | Linoleic acid metabolism | 17 | 1.2545 | 4 | 0.03189 | 1.4963 | 1 | 0.26788 | 1.1875 |
| 11 | Phenylalanine, tyrosine and tryptophan biosynthesis | 11 | 0.81174 | 3 | 0.041937 | 1.3774 | 1 | 0.32025 | 2 |
| 12 | Glutathione metabolism | 56 | 4.1325 | 8 | 0.050154 | 1.2997 | 1 | 0.35108 | 0.61818 |
| 13 | Purine metabolism | 169 | 12.471 | 18 | 0.067518 | 1.1706 | 1 | 0.43627 | 0.6369 |
| 14 | Glycine, serine and threonine metabolism | 72 | 5.3132 | 9 | 0.079296 | 1.1008 | 1 | 0.45891 | 0.88732 |
| 15 | Pentose and glucuronate interconversions | 32 | 2.3614 | 5 | 0.081948 | 1.0865 | 1 | 0.45891 | 0.48387 |
| 16 | Nicotinate and nicotinamide metabolism | 43 | 3.1732 | 6 | 0.09252 | 1.0338 | 1 | 0.48573 | 0.61905 |
| 17 | Pantothenate and CoA biosynthesis | 34 | 2.509 | 5 | 0.10073 | 0.99686 | 1 | 0.49771 | 0.27273 |
| 18 | Taurine and hypotaurine metabolism | 16 | 1.1807 | 3 | 0.10874 | 0.96363 | 1 | 0.50081 | 0.53333 |
| 19 | Terpenoid backbone biosynthesis | 36 | 2.6566 | 5 | 0.12147 | 0.91554 | 1 | 0.50081 | 0.51429 |
| 20 | Primary bile acid biosynthesis | 90 | 6.6415 | 10 | 0.12261 | 0.91149 | 1 | 0.50081 | 0.30337 |
| 21 | Ascorbate and aldarate metabolism | 17 | 1.2545 | 3 | 0.1252 | 0.90238 | 1 | 0.50081 | 0.4375 |
| 22 | Riboflavin metabolism | 9 | 0.66415 | 2 | 0.13843 | 0.85876 | 1 | 0.52857 | 0.625 |
| 23 | Steroid biosynthesis | 82 | 6.0512 | 9 | 0.14637 | 0.83455 | 1 | 0.53305 | 0.4321 |
| 24 | Butanoate metabolism | 29 | 2.14 | 4 | 0.16131 | 0.79233 | 1 | 0.53305 | 0.25 |
| 25 | Nitrogen metabolism | 10 | 0.73795 | 2 | 0.16499 | 0.78254 | 1 | 0.53305 | 0.33333 |
| 26 | D-Glutamine and D-glutamate metabolism | 10 | 0.73795 | 2 | 0.16499 | 0.78254 | 1 | 0.53305 | 0.44444 |
| 27 | Glycerophospholipid metabolism | 86 | 6.3463 | 9 | 0.17939 | 0.7462 | 1 | 0.5581 | 0.48235 |
| 28 | Histidine metabolism | 32 | 2.3614 | 4 | 0.20695 | 0.68414 | 1 | 0.62084 | 0.32258 |
| 29 | Glyoxylate and dicarboxylate metabolism | 56 | 4.1325 | 6 | 0.2285 | 0.64111 | 1 | 0.66186 | 0.23636 |
| 30 | Glycerolipid metabolism | 35 | 2.5828 | 4 | 0.25579 | 0.59212 | 1 | 0.71598 | 0.26471 |
| 31 | Neomycin, kanamycin and gentamicin biosynthesis | 4 | 0.29518 | 1 | 0.26423 | 0.57802 | 1 | 0.71598 | 0.66667 |
| 32 | Starch and sucrose metabolism | 37 | 2.7304 | 4 | 0.28955 | 0.53828 | 1 | 0.73704 | 0.25 |
| 33 | Fructose and mannose metabolism | 37 | 2.7304 | 4 | 0.28955 | 0.53828 | 1 | 0.73704 | 0.36111 |
| 34 | Galactose metabolism | 51 | 3.7635 | 5 | 0.3225 | 0.49148 | 1 | 0.77735 | 0.48 |
| 35 | Ether lipid metabolism | 39 | 2.878 | 4 | 0.3239 | 0.4896 | 1 | 0.77735 | 0.36842 |
| 36 | beta-Alanine metabolism | 44 | 3.247 | 4 | 0.41033 | 0.38687 | 1 | 0.95743 | 0.23256 |
| 37 | Arachidonic acid metabolism | 79 | 5.8298 | 6 | 0.53405 | 0.27242 | 1 | 1 | 0.66667 |
| 38 | Phosphonate and phosphinate metabolism | 10 | 0.73795 | 1 | 0.53611 | 0.27075 | 1 | 1 | 0.22222 |
| 39 | Amino sugar and nucleotide sugar metabolism | 81 | 5.9774 | 6 | 0.55936 | 0.25231 | 1 | 1 | 0.3 |
| 40 | Citrate cycle (TCA cycle) | 42 | 3.0994 | 3 | 0.60989 | 0.21475 | 1 | 1 | 0.39024 |
| 41 | One carbon pool by folate | 31 | 2.2876 | 2 | 0.67961 | 0.16774 | 1 | 1 | 0.3 |
| 42 | Pentose phosphate pathway | 47 | 3.4683 | 3 | 0.68648 | 0.16337 | 1 | 1 | 0.3913 |
| 43 | Arginine and proline metabolism | 78 | 5.756 | 5 | 0.69488 | 0.15809 | 1 | 1 | 0.24675 |
| 44 | Ubiquinone and other terpenoid-quinone biosynthesis | 17 | 1.2545 | 1 | 0.72958 | 0.13693 | 1 | 1 | 0.0625 |
| 45 | Selenocompound metabolism | 35 | 2.5828 | 2 | 0.74327 | 0.12886 | 1 | 1 | 0.20588 |
| 46 | Sulfur metabolism | 18 | 1.3283 | 1 | 0.74968 | 0.12513 | 1 | 1 | 0.11765 |
| 47 | Pyrimidine metabolism | 99 | 7.3057 | 6 | 0.75254 | 0.12347 | 1 | 1 | 0.28571 |
| 48 | Tryptophan metabolism | 84 | 6.1987 | 5 | 0.75604 | 0.12145 | 1 | 1 | 0.28916 |
| 49 | Drug metabolism - other enzymes | 69 | 5.0918 | 4 | 0.76251 | 0.11775 | 1 | 1 | 0.088235 |
| 50 | Porphyrin and chlorophyll metabolism | 53 | 3.9111 | 3 | 0.76296 | 0.1175 | 1 | 1 | 0.076923 |
| 51 | Valine, leucine and isoleucine degradation | 88 | 6.4939 | 5 | 0.79147 | 0.10156 | 1 | 1 | 0.12644 |
| 52 | Tyrosine metabolism | 88 | 6.4939 | 5 | 0.79147 | 0.10156 | 1 | 1 | 0.27586 |
| 53 | Vitamin B6 metabolism | 21 | 1.5497 | 1 | 0.80149 | 0.096104 | 1 | 1 | 0.05 |
| 54 | Biotin metabolism | 21 | 1.5497 | 1 | 0.80149 | 0.096104 | 1 | 1 | 0.05 |
| 55 | Mucin type O-glycan biosynthesis | 22 | 1.6235 | 1 | 0.81627 | 0.088168 | 1 | 1 | 0.14286 |
| 56 | Retinol metabolism | 44 | 3.247 | 2 | 0.84807 | 0.071567 | 1 | 1 | 0.093023 |
| 57 | Glycosaminoglycan degradation | 44 | 3.247 | 2 | 0.84807 | 0.071567 | 1 | 1 | 0.13953 |
| 58 | Pyruvate metabolism | 45 | 3.3208 | 2 | 0.85695 | 0.067046 | 1 | 1 | 0.090909 |
| 59 | Glycosphingolipid biosynthesis - ganglio series | 47 | 3.4683 | 2 | 0.8733 | 0.058837 | 1 | 1 | 0.21739 |
| 60 | Propanoate metabolism | 48 | 3.5421 | 2 | 0.88082 | 0.055115 | 1 | 1 | 0.17021 |
| 61 | Lysine degradation | 49 | 3.6159 | 2 | 0.88792 | 0.051625 | 1 | 1 | 0.083333 |
| 62 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 31 | 2.2876 | 1 | 0.90856 | 0.041645 | 1 | 1 | 0.13333 |
| 63 | Glycosphingolipid biosynthesis - globo and isoglobo series | 31 | 2.2876 | 1 | 0.90856 | 0.041645 | 1 | 1 | 0.13333 |
| 64 | Phosphatidylinositol signaling system | 74 | 5.4608 | 3 | 0.9206 | 0.035928 | 1 | 1 | 0.26027 |
| 65 | Various types of N-glycan biosynthesis | 36 | 2.6566 | 1 | 0.93802 | 0.027786 | 1 | 1 | 0.22857 |
| 66 | Glycolysis or Gluconeogenesis | 61 | 4.5015 | 2 | 0.94752 | 0.02341 | 1 | 1 | 0.16667 |
| 67 | Drug metabolism - cytochrome P450 | 39 | 2.878 | 1 | 0.95094 | 0.021846 | 1 | 1 | 0.078947 |

| | | | | | | | | | |
|----|--|-----|--------|---|---------|----------|---|---|----------|
| 68 | Inositol phosphate metabolism | 69 | 5.0918 | 2 | 0.96893 | 0.013708 | 1 | 1 | 0.073529 |
| 69 | Fatty acid elongation | 75 | 5.5346 | 2 | 0.97919 | 0.009131 | 1 | 1 | 0.054054 |
| 70 | Fatty acid degradation | 102 | 7.527 | 3 | 0.98478 | 0.006659 | 1 | 1 | 0.17822 |
| 71 | Folate biosynthesis | 60 | 4.4277 | 1 | 0.99053 | 0.004132 | 1 | 1 | 0.084746 |
| 72 | N-Glycan biosynthesis | 77 | 5.6822 | 1 | 0.99753 | 0.001075 | 1 | 1 | 0.026316 |
| 73 | Steroid hormone biosynthesis | 175 | 12.914 | 5 | 0.99762 | 0.001033 | 1 | 1 | 0.21839 |
| 74 | Metabolism of xenobiotics by cytochrome P450 | 117 | 8.634 | 2 | 0.99891 | 0.000474 | 1 | 1 | 0.051724 |
| 75 | Fatty acid biosynthesis | 129 | 9.5195 | 2 | 0.99955 | 0.000197 | 1 | 1 | 0.023438 |

Supplemental Table 3: PNPLA3^{I148M} vs Luc on WDSW

| | Pathway | Total number of targets | Expected number of targets | Number of Hits | Raw p-value | Log10(p-value) | Holm adjust | FDR | Impact |
|----|--|-------------------------|----------------------------|----------------|-------------|----------------|-------------|----------|----------|
| 1 | Aminoacyl-tRNA biosynthesis | 74 | 8.3774 | 30 | 4.40E-11 | 10.357 | 3.70E-09 | 3.70E-09 | 0.61644 |
| 2 | Arginine biosynthesis | 27 | 3.0566 | 10 | 0.000427 | 3.37 | 0.035404 | 0.017915 | 0.96154 |
| 3 | Linoleic acid metabolism | 17 | 1.9245 | 7 | 0.001573 | 2.8033 | 0.12899 | 0.044045 | 1.4375 |
| 4 | Nitrogen metabolism | 10 | 1.1321 | 5 | 0.002793 | 2.5539 | 0.22627 | 0.056529 | 0.77778 |
| 5 | Sphingolipid metabolism | 58 | 6.566 | 14 | 0.004063 | 2.3912 | 0.325 | 0.056529 | 1 |
| 6 | Glycerolipid metabolism | 35 | 3.9623 | 10 | 0.004065 | 2.3909 | 0.325 | 0.056529 | 0.58824 |
| 7 | Biosynthesis of unsaturated fatty acids | 47 | 5.3208 | 12 | 0.004711 | 2.3269 | 0.36744 | 0.056529 | 0.69565 |
| 8 | Amino sugar and nucleotide sugar metabolism | 81 | 9.1698 | 17 | 0.007514 | 2.1242 | 0.57855 | 0.073718 | 0.525 |
| 9 | Glutathione metabolism | 56 | 6.3396 | 13 | 0.007898 | 2.1025 | 0.60028 | 0.073718 | 0.70909 |
| 10 | Riboflavin metabolism | 9 | 1.0189 | 4 | 0.012753 | 1.8944 | 0.95646 | 0.10504 | 1.125 |
| 11 | Glycerophospholipid metabolism | 86 | 9.7358 | 17 | 0.013756 | 1.8615 | 1 | 0.10504 | 0.58824 |
| 12 | Alanine, aspartate and glutamate metabolism | 61 | 6.9057 | 12 | 0.03702 | 1.4316 | 1 | 0.24618 | 0.71667 |
| 13 | Valine, leucine and isoleucine biosynthesis | 12 | 1.3585 | 4 | 0.038099 | 1.4191 | 1 | 0.24618 | 0.45455 |
| 14 | Purine metabolism | 169 | 19.132 | 26 | 0.058538 | 1.2326 | 1 | 0.35123 | 0.97024 |
| 15 | Porphyrin and chlorophyll metabolism | 53 | 6 | 10 | 0.069312 | 1.1592 | 1 | 0.38815 | 0.42308 |
| 16 | Nicotinate and nicotinamide metabolism | 43 | 4.8679 | 8 | 0.10509 | 0.97842 | 1 | 0.55174 | 0.7619 |
| 17 | Fructose and mannose metabolism | 37 | 4.1887 | 7 | 0.11687 | 0.9323 | 1 | 0.57747 | 0.52778 |
| 18 | Phenylalanine metabolism | 24 | 2.717 | 5 | 0.12657 | 0.89769 | 1 | 0.59064 | 0.56522 |
| 19 | Pentose and glucuronate interconversions | 32 | 3.6226 | 6 | 0.14568 | 0.83659 | 1 | 0.62957 | 0.67742 |
| 20 | Drug metabolism - other enzymes | 69 | 7.8113 | 11 | 0.1499 | 0.82421 | 1 | 0.62957 | 0.26471 |
| 21 | Cysteine and methionine metabolism | 71 | 8.0377 | 11 | 0.17251 | 0.76319 | 1 | 0.69003 | 0.37143 |
| 22 | alpha-Linolenic acid metabolism | 22 | 2.4906 | 4 | 0.23273 | 0.63314 | 1 | 0.88862 | 0.38095 |
| 23 | Taurine and hypotaurine metabolism | 16 | 1.8113 | 3 | 0.26863 | 0.57084 | 1 | 0.94343 | 0.53333 |
| 24 | One carbon pool by folate | 31 | 3.5094 | 5 | 0.26955 | 0.56936 | 1 | 0.94343 | 0.56667 |
| 25 | Ascorbate and aldarate metabolism | 17 | 1.9245 | 3 | 0.30111 | 0.52128 | 1 | 1 | 0.3125 |
| 26 | D-Glutamine and D-glutamate metabolism | 10 | 1.1321 | 2 | 0.31531 | 0.50127 | 1 | 1 | 0.44444 |
| 27 | Phosphatidylinositol signaling system | 74 | 8.3774 | 10 | 0.32444 | 0.48887 | 1 | 1 | 0.43836 |
| 28 | Pantothenate and CoA biosynthesis | 34 | 3.8491 | 5 | 0.33924 | 0.46949 | 1 | 1 | 0.33333 |
| 29 | Phenylalanine, tyrosine and tryptophan biosynthesis | 11 | 1.2453 | 2 | 0.35887 | 0.44506 | 1 | 1 | 1.2 |
| 30 | Selenocompound metabolism | 35 | 3.9623 | 5 | 0.36286 | 0.44026 | 1 | 1 | 0.35294 |
| 31 | Retinol metabolism | 44 | 4.9811 | 6 | 0.38008 | 0.42013 | 1 | 1 | 0.37209 |
| 32 | Arginine and proline metabolism | 78 | 8.8302 | 10 | 0.38801 | 0.41115 | 1 | 1 | 0.45455 |
| 33 | Pyruvate metabolism | 45 | 5.0943 | 6 | 0.40137 | 0.39646 | 1 | 1 | 0.36364 |
| 34 | Butanoate metabolism | 29 | 3.283 | 4 | 0.41978 | 0.37698 | 1 | 1 | 0.32143 |
| 35 | Biotin metabolism | 21 | 2.3774 | 3 | 0.43053 | 0.36599 | 1 | 1 | 1 |
| 36 | Pentose phosphate pathway | 47 | 5.3208 | 6 | 0.44376 | 0.35285 | 1 | 1 | 0.65217 |
| 37 | Glyoxylate and dicarboxylate metabolism | 56 | 6.3396 | 7 | 0.45169 | 0.34516 | 1 | 1 | 0.34545 |
| 38 | Drug metabolism - cytochrome P450 | 39 | 4.4151 | 5 | 0.45692 | 0.34016 | 1 | 1 | 0.15789 |
| 39 | Lysine degradation | 49 | 5.5472 | 6 | 0.48555 | 0.31377 | 1 | 1 | 0.375 |
| 40 | Inositol phosphate metabolism | 69 | 7.8113 | 8 | 0.52895 | 0.27659 | 1 | 1 | 0.22059 |
| 41 | Pyrimidine metabolism | 99 | 11.208 | 11 | 0.5761 | 0.2395 | 1 | 1 | 0.55102 |
| 42 | Primary bile acid biosynthesis | 90 | 10.189 | 10 | 0.57698 | 0.23884 | 1 | 1 | 0.37079 |
| 43 | Glycine, serine and threonine metabolism | 72 | 8.1509 | 8 | 0.57976 | 0.23675 | 1 | 1 | 0.80282 |
| 44 | Ubiquinone and other terpenoid-quinone biosynthesis | 17 | 1.9245 | 2 | 0.58966 | 0.2294 | 1 | 1 | 0.1875 |
| 45 | Glycosphingolipid biosynthesis - ganglio series | 47 | 5.3208 | 5 | 0.62899 | 0.20136 | 1 | 1 | 0.3913 |
| 46 | Ether lipid metabolism | 39 | 4.4151 | 4 | 0.65994 | 0.1805 | 1 | 1 | 0.31579 |
| 47 | Arachidonic acid metabolism | 79 | 8.9434 | 8 | 0.68721 | 0.16291 | 1 | 1 | 0.64103 |
| 48 | Glycosphingolipid biosynthesis - globo and isoglobo series | 31 | 3.5094 | 3 | 0.69933 | 0.15532 | 1 | 1 | 0.26667 |
| 49 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 31 | 3.5094 | 3 | 0.69933 | 0.15532 | 1 | 1 | 0.33333 |
| 50 | Synthesis and degradation of ketone bodies | 10 | 1.1321 | 1 | 0.69997 | 0.15492 | 1 | 1 | 0.44444 |
| 51 | Galactose metabolism | 51 | 5.7736 | 5 | 0.70157 | 0.15393 | 1 | 1 | 0.48 |
| 52 | Glycolysis or Gluconeogenesis | 61 | 6.9057 | 6 | 0.70533 | 0.15161 | 1 | 1 | 0.33333 |
| 53 | Citrate cycle (TCA cycle) | 42 | 4.7547 | 4 | 0.71744 | 0.14421 | 1 | 1 | 0.53659 |
| 54 | Histidine metabolism | 32 | 3.6226 | 3 | 0.72013 | 0.14259 | 1 | 1 | 0.25806 |
| 55 | Mucin type O-glycan biosynthesis | 22 | 2.4906 | 2 | 0.73045 | 0.13641 | 1 | 1 | 0.2381 |
| 56 | beta-Alanine metabolism | 44 | 4.9811 | 4 | 0.75162 | 0.124 | 1 | 1 | 0.23256 |
| 57 | N-Glycan biosynthesis | 77 | 8.717 | 7 | 0.7868 | 0.10413 | 1 | 1 | 0.21053 |
| 58 | Fatty acid elongation | 75 | 8.4906 | 6 | 0.86922 | 0.06087 | 1 | 1 | 0.10811 |
| 59 | Sulfur metabolism | 18 | 2.0377 | 1 | 0.88592 | 0.052607 | 1 | 1 | 0.70588 |
| 60 | Vitamin B6 metabolism | 21 | 2.3774 | 1 | 0.92069 | 0.035888 | 1 | 1 | 0.05 |
| 61 | Caffeine metabolism | 21 | 2.3774 | 1 | 0.92069 | 0.035888 | 1 | 1 | 0.4 |
| 62 | Propanoate metabolism | 48 | 5.434 | 3 | 0.92225 | 0.035151 | 1 | 1 | 0.23404 |
| 63 | Terpenoid backbone biosynthesis | 36 | 4.0755 | 2 | 0.92745 | 0.032707 | 1 | 1 | 0.057143 |
| 64 | Tryptophan metabolism | 84 | 9.5094 | 6 | 0.92797 | 0.032466 | 1 | 1 | 0.36145 |
| 65 | Starch and sucrose metabolism | 37 | 4.1887 | 2 | 0.9343 | 0.029515 | 1 | 1 | 0.13889 |
| 66 | Glycosaminoglycan degradation | 44 | 4.9811 | 2 | 0.96763 | 0.01429 | 1 | 1 | 0.093023 |
| 67 | Valine, leucine and isoleucine degradation | 88 | 9.9623 | 5 | 0.97821 | 0.009569 | 1 | 1 | 0.2069 |

| | | | | | | | | | |
|----|--|-----|--------|----|---------|----------|---|---|----------|
| 68 | Tyrosine metabolism | 88 | 9.9623 | 5 | 0.97821 | 0.009569 | 1 | 1 | 0.37931 |
| 69 | Steroid biosynthesis | 82 | 9.283 | 4 | 0.98795 | 0.005267 | 1 | 1 | 0.20988 |
| 70 | Folate biosynthesis | 60 | 6.7925 | 2 | 0.99403 | 0.0026 | 1 | 1 | 0.25424 |
| 71 | Steroid hormone biosynthesis | 175 | 19.811 | 10 | 0.99712 | 0.001253 | 1 | 1 | 0.21839 |
| 72 | Metabolism of xenobiotics by cytochrome P450 | 117 | 13.245 | 4 | 0.99958 | 0.000181 | 1 | 1 | 0.25862 |
| 73 | Fatty acid degradation | 102 | 11.547 | 2 | 0.99995 | 2.28E-05 | 1 | 1 | 0.059406 |
| 74 | Fatty acid biosynthesis | 129 | 14.604 | 3 | 0.99998 | 8.68E-06 | 1 | 1 | 0.070312 |
| 75 | Glycosphingolipid biosynthesis - lacto and neolacto series | 102 | 11.547 | 1 | 1 | 1.56E-06 | 1 | 1 | 0.019802 |

Supplemental Table 4: PNPLA3^{I148M} vs PNPLA3^{WT} on WDSW

| | Pathway | Total number of targets | Expected number of targets | Number of Hits | Raw p-value | Log10(p-value) | Holm adjust | FDR | Impact |
|----|---|-------------------------|----------------------------|----------------|-------------|----------------|-------------|----------|----------|
| 1 | Central carbon metabolism in cancer | 104 | 1.8961 | 22 | 9.87E-18 | 17.006 | 3.23E-15 | 3.23E-15 | 0.098214 |
| 2 | Aminoacyl-tRNA biosynthesis | 118 | 2.1513 | 21 | 2.32E-15 | 14.635 | 7.55E-13 | 3.79E-13 | 0.25773 |
| 3 | ABC transporters | 186 | 3.3911 | 22 | 2.88E-12 | 11.541 | 9.35E-10 | 3.13E-10 | 0 |
| 4 | Protein digestion and absorption | 141 | 2.5706 | 18 | 8.33E-11 | 10.079 | 2.70E-08 | 6.81E-09 | 0 |
| 5 | Mineral absorption | 81 | 1.4768 | 13 | 2.17E-09 | 8.6635 | 7.01E-07 | 1.18E-07 | 0 |
| 6 | Biosynthesis of unsaturated fatty acids | 81 | 1.4768 | 13 | 2.17E-09 | 8.6635 | 7.01E-07 | 1.18E-07 | 0.075758 |
| 7 | Alanine, aspartate and glutamate metabolism | 66 | 1.2033 | 9 | 2.84E-06 | 5.5468 | 0.000911 | 0.000133 | 0.67213 |
| 8 | Glycine, serine and threonine metabolism | 90 | 1.6408 | 10 | 5.30E-06 | 5.2759 | 0.001695 | 0.000217 | 0.54545 |
| 9 | Cholesterol metabolism | 59 | 1.0757 | 8 | 1.07E-05 | 4.9701 | 0.003417 | 0.000389 | 0.034188 |
| 10 | Primary bile acid biosynthesis | 63 | 1.1486 | 8 | 1.76E-05 | 4.7551 | 0.005589 | 0.000575 | 0.15957 |
| 11 | Linoleic acid metabolism | 78 | 1.4221 | 8 | 8.42E-05 | 4.0748 | 0.026687 | 0.002334 | 0.73171 |
| 12 | Purine metabolism | 231 | 4.2115 | 14 | 8.57E-05 | 4.0673 | 0.027066 | 0.002334 | 0.64706 |
| 13 | Arginine biosynthesis | 42 | 0.76572 | 6 | 0.000104 | 3.9831 | 0.032752 | 0.002511 | 0.4 |
| 14 | Glutathione metabolism | 103 | 1.8778 | 9 | 0.000107 | 3.9687 | 0.03375 | 0.002511 | 0.73913 |
| 15 | Vitamin digestion and absorption | 63 | 1.1486 | 7 | 0.000142 | 3.8492 | 0.044294 | 0.003085 | 0 |
| 16 | Cysteine and methionine metabolism | 115 | 2.0966 | 9 | 0.000249 | 3.603 | 0.077831 | 0.005098 | 0.24272 |
| 17 | Taurine and hypotaurine metabolism | 33 | 0.60164 | 5 | 0.000301 | 3.5211 | 0.093684 | 0.005794 | 0.27586 |
| 18 | Ferroptosis | 72 | 1.3127 | 7 | 0.000328 | 3.484 | 0.1017 | 0.00596 | 0.027027 |
| 19 | Amino sugar and nucleotide sugar metabolism | 157 | 2.8624 | 10 | 0.000601 | 3.2213 | 0.18563 | 0.010295 | 0.26087 |
| 20 | Antifolate resistance | 58 | 1.0574 | 6 | 0.00063 | 3.2009 | 0.19393 | 0.010295 | 0 |
| 21 | Phenylalanine, tyrosine and tryptophan biosynthesis | 43 | 0.78396 | 5 | 0.001054 | 2.9772 | 0.32355 | 0.016411 | 0.29268 |
| 22 | Valine, leucine and isoleucine biosynthesis | 27 | 0.49225 | 4 | 0.001357 | 2.8674 | 0.4153 | 0.020173 | 0.19231 |
| 23 | Aldosterone synthesis and secretion | 123 | 2.2425 | 8 | 0.001839 | 2.7355 | 0.56079 | 0.026141 | 0 |
| 24 | Nicotinate and nicotinamide metabolism | 98 | 1.7867 | 7 | 0.002069 | 2.6843 | 0.62883 | 0.02763 | 0.2439 |
| 25 | Sphingolipid metabolism | 73 | 1.3309 | 6 | 0.002112 | 2.6752 | 0.64005 | 0.02763 | 1.082 |
| 26 | Fat digestion and absorption | 53 | 0.96627 | 5 | 0.002712 | 2.5667 | 0.81903 | 0.033554 | 0.045455 |
| 27 | Fatty acid biosynthesis | 77 | 1.4038 | 6 | 0.002771 | 2.5574 | 0.83392 | 0.033554 | 0.063953 |
| 28 | Nitrogen metabolism | 36 | 0.65634 | 4 | 0.004009 | 2.397 | 1 | 0.045454 | 0.1087 |
| 29 | Phenylalanine metabolism | 83 | 1.5132 | 6 | 0.004031 | 2.3946 | 1 | 0.045454 | 0.20548 |
| 30 | Synaptic vesicle cycle | 89 | 1.6226 | 6 | 0.005673 | 2.2462 | 1 | 0.061837 | 0.029412 |
| 31 | beta-Alanine metabolism | 64 | 1.1668 | 5 | 0.006133 | 2.2123 | 1 | 0.064698 | 0.11111 |
| 32 | Sulfur metabolism | 44 | 0.80219 | 4 | 0.00825 | 2.0835 | 1 | 0.084308 | 0 |
| 33 | Starch and sucrose metabolism | 70 | 1.2762 | 5 | 0.00892 | 2.0496 | 1 | 0.08839 | 0.17808 |
| 34 | Pantothenate and CoA biosynthesis | 46 | 0.83865 | 4 | 0.009642 | 2.0158 | 1 | 0.092735 | 0.16667 |
| 35 | Galactose metabolism | 78 | 1.4221 | 5 | 0.013851 | 1.8585 | 1 | 0.12941 | 0.42254 |
| 36 | Oxidative phosphorylation | 149 | 2.7165 | 7 | 0.019346 | 1.7134 | 1 | 0.17573 | 0.007299 |
| 37 | Drug metabolism - other enzymes | 151 | 2.753 | 7 | 0.020649 | 1.6851 | 1 | 0.18249 | 0.4 |
| 38 | Pentose and glucuronate interconversions | 89 | 1.6226 | 5 | 0.023225 | 1.634 | 1 | 0.19986 | 0.23529 |
| 39 | Pyrimidine metabolism | 123 | 2.2425 | 6 | 0.025035 | 1.6015 | 1 | 0.20991 | 0.31008 |
| 40 | Glyoxylate and dicarboxylate metabolism | 93 | 1.6955 | 5 | 0.02745 | 1.5615 | 1 | 0.22441 | 0.079545 |
| 41 | Lysosome | 128 | 2.3336 | 6 | 0.029682 | 1.5275 | 1 | 0.23673 | 0 |
| 42 | Proximal tubule bicarbonate reclamation | 39 | 0.71103 | 3 | 0.033765 | 1.4715 | 1 | 0.26289 | 0 |
| 43 | Bile secretion | 246 | 4.485 | 9 | 0.036476 | 1.438 | 1 | 0.27318 | 0.014085 |
| 44 | Butanoate metabolism | 69 | 1.258 | 4 | 0.037043 | 1.4313 | 1 | 0.27318 | 0.090909 |
| 45 | D-Glutamine and D-glutamate metabolism | 17 | 0.30994 | 2 | 0.037594 | 1.4249 | 1 | 0.27318 | 0.25 |
| 46 | Regulation of lipolysis in adipocytes | 70 | 1.2762 | 4 | 0.038747 | 1.4118 | 1 | 0.27544 | 0.033333 |
| 47 | Renal cell carcinoma | 71 | 1.2944 | 4 | 0.040496 | 1.3926 | 1 | 0.28175 | 0.33333 |
| 48 | Choline metabolism in cancer | 109 | 1.9872 | 5 | 0.049055 | 1.3093 | 1 | 0.33419 | 0.037736 |
| 49 | Thiamine metabolism | 46 | 0.83865 | 3 | 0.05117 | 1.291 | 1 | 0.34148 | 0 |
| 50 | Salmonella infection | 79 | 1.4403 | 4 | 0.056075 | 1.2512 | 1 | 0.36673 | 0.22917 |
| 51 | Ovarian steroidogenesis | 81 | 1.4768 | 4 | 0.060409 | 1.2189 | 1 | 0.38733 | 0 |
| 52 | Endocytosis | 275 | 5.0137 | 9 | 0.064938 | 1.1875 | 1 | 0.40836 | 0.058394 |
| 53 | Peroxisome | 84 | 1.5314 | 4 | 0.067232 | 1.1724 | 1 | 0.41481 | 0 |
| 54 | Taste transduction | 121 | 2.206 | 5 | 0.070369 | 1.1526 | 1 | 0.41731 | 0.11429 |
| 55 | Phospholipase D signaling pathway | 159 | 2.8988 | 6 | 0.070938 | 1.1491 | 1 | 0.41731 | 0.11594 |
| 56 | Ras signaling pathway | 239 | 4.3573 | 8 | 0.071466 | 1.1459 | 1 | 0.41731 | 0.44792 |
| 57 | Rheumatoid arthritis | 89 | 1.6226 | 4 | 0.079451 | 1.0999 | 1 | 0.44921 | 0 |
| 58 | Arachidonic acid metabolism | 164 | 2.99 | 6 | 0.079677 | 1.0987 | 1 | 0.44921 | 1.0085 |
| 59 | Arginine and proline metabolism | 128 | 2.3336 | 5 | 0.08482 | 1.0715 | 1 | 0.47011 | 0.16239 |
| 60 | Maturity onset diabetes of the young | 27 | 0.49225 | 2 | 0.086259 | 1.0642 | 1 | 0.47011 | 0.11765 |
| 61 | Insulin resistance | 130 | 2.3701 | 5 | 0.089216 | 1.0496 | 1 | 0.47361 | 0.088235 |
| 62 | Riboflavin metabolism | 28 | 0.51048 | 2 | 0.091817 | 1.0371 | 1 | 0.47361 | 0.20833 |
| 63 | One carbon pool by folate | 28 | 0.51048 | 2 | 0.091817 | 1.0371 | 1 | 0.47361 | 0.23333 |
| 64 | Thyroid hormone synthesis | 94 | 1.7138 | 4 | 0.092694 | 1.033 | 1 | 0.47361 | 0 |
| 65 | FoxO signaling pathway | 136 | 2.4795 | 5 | 0.1031 | 0.98675 | 1 | 0.50185 | 0.071429 |
| 66 | GABAergic synapse | 98 | 1.7867 | 4 | 0.10399 | 0.98299 | 1 | 0.50185 | 0.071429 |
| 67 | Valine, leucine and isoleucine degradation | 98 | 1.7867 | 4 | 0.10399 | 0.98299 | 1 | 0.50185 | 0.19792 |
| 68 | Rap1 signaling pathway | 219 | 3.9927 | 7 | 0.10607 | 0.9744 | 1 | 0.50185 | 0.18085 |
| 69 | Glycerolipid metabolism | 99 | 1.8049 | 4 | 0.10691 | 0.97097 | 1 | 0.50185 | 0.32759 |
| 70 | Mitophagy - animal | 63 | 1.1486 | 3 | 0.10743 | 0.96887 | 1 | 0.50185 | 0.14286 |

| | | | | | | | | | |
|-----|--|-----|---------|----|---------|---------|---|---------|----------|
| 71 | Sphingolipid signaling pathway | 139 | 2.5342 | 5 | 0.11042 | 0.95696 | 1 | 0.50854 | 0.060976 |
| 72 | Morphine addiction | 103 | 1.8778 | 4 | 0.11896 | 0.92462 | 1 | 0.54026 | 0.07 |
| 73 | Pentose phosphate pathway | 67 | 1.2215 | 3 | 0.12313 | 0.90963 | 1 | 0.54425 | 0.42857 |
| 74 | Autophagy - animal | 144 | 2.6253 | 5 | 0.12316 | 0.90952 | 1 | 0.54425 | 0.066667 |
| 75 | Pyruvate metabolism | 69 | 1.258 | 3 | 0.13128 | 0.8818 | 1 | 0.56485 | 0.075472 |
| 76 | alpha-Linolenic acid metabolism | 69 | 1.258 | 3 | 0.13128 | 0.8818 | 1 | 0.56485 | 0.11538 |
| 77 | Collecting duct acid secretion | 35 | 0.6381 | 2 | 0.13327 | 0.87526 | 1 | 0.56597 | 0 |
| 78 | Glycerophospholipid metabolism | 149 | 2.7165 | 5 | 0.13656 | 0.86468 | 1 | 0.5725 | 0.35238 |
| 79 | Histidine metabolism | 71 | 1.2944 | 3 | 0.13961 | 0.85508 | 1 | 0.57788 | 0.12903 |
| 80 | Bacterial invasion of epithelial cells | 73 | 1.3309 | 3 | 0.14812 | 0.8294 | 1 | 0.60341 | 0.069767 |
| 81 | cAMP signaling pathway | 240 | 4.3756 | 7 | 0.14947 | 0.82545 | 1 | 0.60341 | 0.081967 |
| 82 | Leishmaniasis | 74 | 1.3491 | 3 | 0.15243 | 0.81693 | 1 | 0.60786 | 0.09434 |
| 83 | Lysine degradation | 115 | 2.0966 | 4 | 0.1583 | 0.80052 | 1 | 0.61998 | 0.051948 |
| 84 | Parkinson disease | 157 | 2.8624 | 5 | 0.15926 | 0.79789 | 1 | 0.61998 | 0.029851 |
| 85 | Ascorbate and aldarate metabolism | 76 | 1.3856 | 3 | 0.16118 | 0.7927 | 1 | 0.62006 | 0.090909 |
| 86 | Tyrosine metabolism | 118 | 2.1513 | 4 | 0.16881 | 0.77259 | 1 | 0.63923 | 0.14516 |
| 87 | Pancreatic cancer | 78 | 1.4221 | 3 | 0.17007 | 0.76937 | 1 | 0.63923 | 0.087719 |
| 88 | Amoebiasis | 120 | 2.1878 | 4 | 0.17596 | 0.75459 | 1 | 0.65384 | 0.035088 |
| 89 | Cell cycle | 123 | 2.2425 | 4 | 0.18686 | 0.72848 | 1 | 0.67823 | 0.12727 |
| 90 | Retrograde endocannabinoid signaling | 167 | 3.0447 | 5 | 0.18962 | 0.72212 | 1 | 0.67823 | 0.02381 |
| 91 | Proteoglycans in cancer | 212 | 3.8651 | 6 | 0.19102 | 0.71893 | 1 | 0.67823 | 0.09 |
| 92 | Prolactin signaling pathway | 83 | 1.5132 | 3 | 0.19289 | 0.71469 | 1 | 0.67823 | 0.10606 |
| 93 | EGFR tyrosine kinase inhibitor resistance | 83 | 1.5132 | 3 | 0.19289 | 0.71469 | 1 | 0.67823 | 0.19697 |
| 94 | Neurotrophin signaling pathway | 126 | 2.2972 | 4 | 0.19798 | 0.70339 | 1 | 0.67946 | 0.060976 |
| 95 | Yersinia infection | 126 | 2.2972 | 4 | 0.19798 | 0.70339 | 1 | 0.67946 | 0.13684 |
| 96 | Neuroactive ligand-receptor interaction | 402 | 7.3291 | 10 | 0.19947 | 0.70011 | 1 | 0.67946 | 0.073864 |
| 97 | African trypanosomiasis | 46 | 0.83865 | 2 | 0.20448 | 0.68934 | 1 | 0.68351 | 0 |
| 98 | Neomycin, kanamycin and gentamicin biosynthesis | 86 | 1.5679 | 3 | 0.20693 | 0.68417 | 1 | 0.68351 | 0.02381 |
| 99 | Pertussis | 86 | 1.5679 | 3 | 0.20693 | 0.68417 | 1 | 0.68351 | 0.074627 |
| 100 | Nicotine addiction | 47 | 0.85688 | 2 | 0.21118 | 0.67536 | 1 | 0.68994 | 0.078125 |
| 101 | Glucagon signaling pathway | 130 | 2.3701 | 4 | 0.2131 | 0.67141 | 1 | 0.68994 | 0 |
| 102 | Regulation of actin cytoskeleton | 221 | 4.0292 | 6 | 0.21657 | 0.6644 | 1 | 0.6943 | 0.20482 |
| 103 | Fructose and mannose metabolism | 89 | 1.6226 | 3 | 0.2212 | 0.65522 | 1 | 0.70226 | 0.14865 |
| 104 | Phagosome | 181 | 3.2999 | 5 | 0.23521 | 0.62855 | 1 | 0.7339 | 0 |
| 105 | PPAR signaling pathway | 92 | 1.6773 | 3 | 0.23566 | 0.62772 | 1 | 0.7339 | 0.18644 |
| 106 | Renin secretion | 93 | 1.6955 | 3 | 0.24051 | 0.61886 | 1 | 0.73467 | 0.017857 |
| 107 | Porphyrin and chlorophyll metabolism | 183 | 3.3364 | 5 | 0.24196 | 0.61625 | 1 | 0.73467 | 0.037037 |
| 108 | Ubiquitin mediated proteolysis | 138 | 2.516 | 4 | 0.24424 | 0.61217 | 1 | 0.73467 | 0 |
| 109 | Citrate cycle (TCA cycle) | 52 | 0.94804 | 2 | 0.24489 | 0.61103 | 1 | 0.73467 | 0.18182 |
| 110 | Fc gamma R-mediated phagocytosis | 98 | 1.7867 | 3 | 0.26503 | 0.57671 | 1 | 0.78785 | 0.12963 |
| 111 | Cocaine addiction | 56 | 1.021 | 2 | 0.27202 | 0.5654 | 1 | 0.80135 | 0.024691 |
| 112 | AMPK signaling pathway | 149 | 2.7165 | 4 | 0.28854 | 0.53979 | 1 | 0.84244 | 0.010638 |
| 113 | Sulfur relay system | 19 | 0.3464 | 1 | 0.29521 | 0.52986 | 1 | 0.85429 | 0 |
| 114 | Fluid shear stress and atherosclerosis | 152 | 2.7712 | 4 | 0.30083 | 0.52168 | 1 | 0.86291 | 0.10476 |
| 115 | Legionellosis | 61 | 1.1121 | 2 | 0.30586 | 0.51447 | 1 | 0.86972 | 0.065217 |
| 116 | Phosphonate and phosphinate metabolism | 63 | 1.1486 | 2 | 0.31933 | 0.49576 | 1 | 0.90019 | 0 |
| 117 | Prostate cancer | 110 | 2.0055 | 3 | 0.32479 | 0.48839 | 1 | 0.90223 | 0.065574 |
| 118 | mTOR signaling pathway | 158 | 2.8806 | 4 | 0.32557 | 0.48735 | 1 | 0.90223 | 0.035714 |
| 119 | JAK-STAT signaling pathway | 165 | 3.0082 | 4 | 0.3546 | 0.45026 | 1 | 0.96679 | 0.19444 |
| 120 | Retinol metabolism | 116 | 2.1149 | 3 | 0.35478 | 0.45004 | 1 | 0.96679 | 0.67797 |
| 121 | Fatty acid elongation | 69 | 1.258 | 2 | 0.35931 | 0.44453 | 1 | 0.97103 | 0.063291 |
| 122 | Long-term depression | 70 | 1.2762 | 2 | 0.3659 | 0.43664 | 1 | 0.98072 | 0.1087 |
| 123 | p53 signaling pathway | 71 | 1.2944 | 2 | 0.37245 | 0.42893 | 1 | 0.99018 | 0.046875 |
| 124 | Ether lipid metabolism | 72 | 1.3127 | 2 | 0.37899 | 0.42138 | 1 | 0.99942 | 0.2093 |
| 125 | Caffeine metabolism | 28 | 0.51048 | 1 | 0.40296 | 0.39473 | 1 | 1 | 0 |
| 126 | Steroid biosynthesis | 77 | 1.4038 | 2 | 0.4112 | 0.38595 | 1 | 1 | 0.091837 |
| 127 | Amphetamine addiction | 78 | 1.4221 | 2 | 0.41754 | 0.3793 | 1 | 1 | 0.038462 |
| 128 | Glioma | 78 | 1.4221 | 2 | 0.41754 | 0.3793 | 1 | 1 | 0.054795 |
| 129 | Adipocytokine signaling pathway | 78 | 1.4221 | 2 | 0.41754 | 0.3793 | 1 | 1 | 0.069767 |
| 130 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 79 | 1.4403 | 2 | 0.42385 | 0.37278 | 1 | 1 | 0 |
| 131 | Tryptophan metabolism | 130 | 2.3701 | 3 | 0.42386 | 0.37278 | 1 | 1 | 0.088 |
| 132 | Transcriptional misregulation in cancer | 183 | 3.3364 | 4 | 0.4289 | 0.36764 | 1 | 1 | 0.009901 |
| 133 | Biotin metabolism | 31 | 0.56518 | 1 | 0.4351 | 0.36141 | 1 | 1 | 0.026316 |
| 134 | Cortisol synthesis and secretion | 81 | 1.4768 | 2 | 0.43637 | 0.36015 | 1 | 1 | 0 |
| 135 | Necroptosis | 186 | 3.3911 | 4 | 0.44111 | 0.35545 | 1 | 1 | 0.021277 |
| 136 | Circadian rhythm | 32 | 0.58341 | 1 | 0.44543 | 0.35122 | 1 | 1 | 0.05 |
| 137 | Folate biosynthesis | 83 | 1.5132 | 2 | 0.44874 | 0.34801 | 1 | 1 | 0.19101 |
| 138 | Steroid hormone biosynthesis | 188 | 3.4275 | 4 | 0.44921 | 0.34755 | 1 | 1 | 0.25888 |
| 139 | SNARE interactions in vesicular transport | 33 | 0.60164 | 1 | 0.45557 | 0.34145 | 1 | 1 | 0.026316 |
| 140 | MAPK signaling pathway | 299 | 5.4512 | 6 | 0.46436 | 0.33315 | 1 | 1 | 0.15323 |
| 141 | Apoptosis | 140 | 2.5524 | 3 | 0.47165 | 0.32638 | 1 | 1 | 0.072072 |
| 142 | Chemical carcinogenesis | 194 | 3.5369 | 4 | 0.47328 | 0.32488 | 1 | 1 | 0.067568 |
| 143 | Autophagy - other | 35 | 0.6381 | 1 | 0.47529 | 0.32304 | 1 | 1 | 0.027778 |
| 144 | Estrogen signaling pathway | 142 | 2.5889 | 3 | 0.481 | 0.31786 | 1 | 1 | 0.064935 |

| | | | | | | | | | |
|-----|---|-----|---------|----|---------|----------|---|---|----------|
| 145 | PI3K-Akt signaling pathway | 359 | 6.5451 | 7 | 0.48261 | 0.3164 | 1 | 1 | 0.079208 |
| 146 | Colorectal cancer | 89 | 1.6226 | 2 | 0.4849 | 0.31435 | 1 | 1 | 0.040541 |
| 147 | Complement and coagulation cascades | 89 | 1.6226 | 2 | 0.4849 | 0.31435 | 1 | 1 | 0.046154 |
| 148 | Insulin signaling pathway | 143 | 2.6071 | 3 | 0.48564 | 0.31368 | 1 | 1 | 0.12121 |
| 149 | Prion diseases | 37 | 0.67457 | 1 | 0.4943 | 0.30601 | 1 | 1 | 0 |
| 150 | Vitamin B6 metabolism | 37 | 0.67457 | 1 | 0.4943 | 0.30601 | 1 | 1 | 0.025641 |
| 151 | IL-17 signaling pathway | 91 | 1.6591 | 2 | 0.49663 | 0.30397 | 1 | 1 | 0 |
| 152 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 92 | 1.6773 | 2 | 0.50242 | 0.29893 | 1 | 1 | 0.0625 |
| 153 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 39 | 0.71103 | 1 | 0.51263 | 0.29019 | 1 | 1 | 0.093023 |
| 154 | Progesterone-mediated oocyte maturation | 94 | 1.7138 | 2 | 0.51389 | 0.28913 | 1 | 1 | 0.025 |
| 155 | Hypertrophic cardiomyopathy (HCM) | 94 | 1.7138 | 2 | 0.51389 | 0.28913 | 1 | 1 | 0.043478 |
| 156 | GnRH signaling pathway | 96 | 1.7502 | 2 | 0.52519 | 0.27969 | 1 | 1 | 0.042553 |
| 157 | Gap junction | 97 | 1.7685 | 2 | 0.53077 | 0.27509 | 1 | 1 | 0.038462 |
| 158 | Dilated cardiomyopathy (DCM) | 97 | 1.7685 | 2 | 0.53077 | 0.27509 | 1 | 1 | 0.043478 |
| 159 | Glycolysis or Gluconeogenesis | 97 | 1.7685 | 2 | 0.53077 | 0.27509 | 1 | 1 | 0.26154 |
| 160 | Longevity regulating pathway | 98 | 1.7867 | 2 | 0.53631 | 0.27059 | 1 | 1 | 0.055556 |
| 161 | Alcoholism | 211 | 3.8469 | 4 | 0.53913 | 0.26831 | 1 | 1 | 0.02 |
| 162 | Toll-like receptor signaling pathway | 99 | 1.8049 | 2 | 0.5418 | 0.26616 | 1 | 1 | 0.048193 |
| 163 | Fatty acid degradation | 100 | 1.8232 | 2 | 0.54724 | 0.26182 | 1 | 1 | 0.058824 |
| 164 | Nucleotide excision repair | 43 | 0.78396 | 1 | 0.54733 | 0.26175 | 1 | 1 | 0 |
| 165 | Selenocompound metabolism | 44 | 0.80219 | 1 | 0.55561 | 0.25523 | 1 | 1 | 0.02381 |
| 166 | Ubiquinone and other terpenoid-quinone biosynthesis | 103 | 1.8778 | 2 | 0.56331 | 0.24925 | 1 | 1 | 0.046512 |
| 167 | Inflammatory mediator regulation of TRP channels | 162 | 2.9535 | 3 | 0.56976 | 0.24431 | 1 | 1 | 0.044944 |
| 168 | Proteasome | 46 | 0.83865 | 1 | 0.57172 | 0.24281 | 1 | 1 | 0 |
| 169 | Kaposi sarcoma-associated herpesvirus infection | 221 | 4.0292 | 4 | 0.57588 | 0.23967 | 1 | 1 | 0.091603 |
| 170 | Th17 cell differentiation | 106 | 1.9325 | 2 | 0.57897 | 0.23735 | 1 | 1 | 0.028571 |
| 171 | Renin-angiotensin system | 47 | 0.85688 | 1 | 0.57956 | 0.2369 | 1 | 1 | 0.025641 |
| 172 | Tight junction | 167 | 3.0447 | 3 | 0.59046 | 0.22881 | 1 | 1 | 0.088889 |
| 173 | Pathways in cancer | 570 | 10.392 | 10 | 0.59561 | 0.22504 | 1 | 1 | 0.084112 |
| 174 | Influenza A | 169 | 3.0811 | 3 | 0.59856 | 0.2229 | 1 | 1 | 0.035398 |
| 175 | Drug metabolism - cytochrome P450 | 169 | 3.0811 | 3 | 0.59856 | 0.2229 | 1 | 1 | 0.084906 |
| 176 | AGE-RAGE signaling pathway in diabetic complications | 110 | 2.0055 | 2 | 0.5992 | 0.22243 | 1 | 1 | 0.074627 |
| 177 | Fanconi anemia pathway | 51 | 0.92981 | 1 | 0.60951 | 0.21502 | 1 | 1 | 0.12963 |
| 178 | TNF signaling pathway | 113 | 2.0602 | 2 | 0.61389 | 0.21191 | 1 | 1 | 0 |
| 179 | NF-kappa B signaling pathway | 113 | 2.0602 | 2 | 0.61389 | 0.21191 | 1 | 1 | 0.01875 |
| 180 | Serotonergic synapse | 173 | 3.1541 | 3 | 0.61444 | 0.21152 | 1 | 1 | 0 |
| 181 | Type II diabetes mellitus | 54 | 0.9845 | 1 | 0.63057 | 0.20027 | 1 | 1 | 0.064516 |
| 182 | Parathyroid hormone synthesis, secretion and action | 117 | 2.1331 | 2 | 0.63284 | 0.19871 | 1 | 1 | 0 |
| 183 | Axon guidance | 181 | 3.2999 | 3 | 0.64492 | 0.19049 | 1 | 1 | 0.10067 |
| 184 | Glutamatergic synapse | 121 | 2.206 | 2 | 0.65105 | 0.18638 | 1 | 1 | 0.18571 |
| 185 | Staphylococcus aureus infection | 123 | 2.2425 | 2 | 0.65989 | 0.18053 | 1 | 1 | 0.025641 |
| 186 | Oocyte meiosis | 123 | 2.2425 | 2 | 0.65989 | 0.18053 | 1 | 1 | 0.10588 |
| 187 | C-type lectin receptor signaling pathway | 124 | 2.2607 | 2 | 0.66424 | 0.17767 | 1 | 1 | 0.036842 |
| 188 | Inflammatory bowel disease (IBD) | 60 | 1.0939 | 1 | 0.66936 | 0.17434 | 1 | 1 | 0.032258 |
| 189 | Metabolism of xenobiotics by cytochrome P450 | 188 | 3.4275 | 3 | 0.67017 | 0.17381 | 1 | 1 | 0.37363 |
| 190 | Human T-cell leukemia virus 1 infection | 251 | 4.5761 | 4 | 0.67548 | 0.17039 | 1 | 1 | 0.023077 |
| 191 | HIF-1 signaling pathway | 127 | 2.3154 | 2 | 0.67703 | 0.16939 | 1 | 1 | 0.46341 |
| 192 | Amyotrophic lateral sclerosis (ALS) | 62 | 1.1304 | 1 | 0.68136 | 0.16662 | 1 | 1 | 0.018519 |
| 193 | Thermogenesis | 253 | 4.6126 | 4 | 0.68151 | 0.16653 | 1 | 1 | 0 |
| 194 | Basal cell carcinoma | 64 | 1.1668 | 1 | 0.69294 | 0.15931 | 1 | 1 | 0 |
| 195 | VEGF signaling pathway | 64 | 1.1668 | 1 | 0.69294 | 0.15931 | 1 | 1 | 0.060606 |
| 196 | Osteoclast differentiation | 131 | 2.3883 | 2 | 0.69346 | 0.15898 | 1 | 1 | 0.13158 |
| 197 | Cytosolic DNA-sensing pathway | 65 | 1.1851 | 1 | 0.69856 | 0.15579 | 1 | 1 | 0.125 |
| 198 | Endocrine and other factor-regulated calcium reabsorption | 68 | 1.2397 | 1 | 0.71484 | 0.14579 | 1 | 1 | 0 |
| 199 | RIG-I-like receptor signaling pathway | 68 | 1.2397 | 1 | 0.71484 | 0.14579 | 1 | 1 | 0.056604 |
| 200 | Platelet activation | 139 | 2.5342 | 2 | 0.72425 | 0.14011 | 1 | 1 | 0.046512 |
| 201 | Acute myeloid leukemia | 71 | 1.2944 | 1 | 0.73024 | 0.13653 | 1 | 1 | 0.020833 |
| 202 | Adherens junction | 71 | 1.2944 | 1 | 0.73024 | 0.13653 | 1 | 1 | 0.093333 |
| 203 | GnRH secretion | 72 | 1.3127 | 1 | 0.73519 | 0.1336 | 1 | 1 | 0 |
| 204 | Non-small cell lung cancer | 72 | 1.3127 | 1 | 0.73519 | 0.1336 | 1 | 1 | 0.035714 |
| 205 | Melanoma | 73 | 1.3309 | 1 | 0.74004 | 0.13074 | 1 | 1 | 0.030303 |
| 206 | Long-term potentiation | 74 | 1.3491 | 1 | 0.74481 | 0.12795 | 1 | 1 | 0.096774 |
| 207 | Systemic lupus erythematosus | 145 | 2.6436 | 2 | 0.74561 | 0.12749 | 1 | 1 | 0.085106 |
| 208 | NOD-like receptor signaling pathway | 215 | 3.9198 | 3 | 0.75521 | 0.12193 | 1 | 1 | 0.054545 |
| 209 | Fc epsilon RI signaling pathway | 78 | 1.4221 | 1 | 0.76303 | 0.11746 | 1 | 1 | 0.02 |
| 210 | Non-alcoholic fatty liver disease (NAFLD) | 152 | 2.7712 | 2 | 0.76872 | 0.11423 | 1 | 1 | 0.058824 |
| 211 | Platinum drug resistance | 81 | 1.4768 | 1 | 0.77584 | 0.11023 | 1 | 1 | 0 |
| 212 | Propanoate metabolism | 81 | 1.4768 | 1 | 0.77584 | 0.11023 | 1 | 1 | 0.027778 |
| 213 | RNA degradation | 82 | 1.495 | 1 | 0.77995 | 0.10793 | 1 | 1 | 0 |
| 214 | Vascular smooth muscle contraction | 156 | 2.8441 | 2 | 0.7811 | 0.10729 | 1 | 1 | 0.028169 |
| 215 | Human papillomavirus infection | 364 | 6.6363 | 5 | 0.79799 | 0.098002 | 1 | 1 | 0.03125 |

| | | | | | | | | | |
|-----|---|------|--------|---|---------|----------|---|---|----------|
| 216 | Hepatitis B | 163 | 2.9717 | 2 | 0.80137 | 0.096168 | 1 | 1 | 0.007407 |
| 217 | N-Glycan biosynthesis | 88 | 1.6044 | 1 | 0.80311 | 0.095226 | 1 | 1 | 0.037975 |
| 218 | ErbB signaling pathway | 88 | 1.6044 | 1 | 0.80311 | 0.095226 | 1 | 1 | 0.043478 |
| 219 | MicroRNAs in cancer | 303 | 5.5242 | 4 | 0.80719 | 0.093023 | 1 | 1 | 0.009132 |
| 220 | Th1 and Th2 cell differentiation | 90 | 1.6408 | 1 | 0.81027 | 0.091368 | 1 | 1 | 0.042254 |
| 221 | Cardiac muscle contraction | 90 | 1.6408 | 1 | 0.81027 | 0.091368 | 1 | 1 | 0.093023 |
| 222 | Antigen processing and presentation | 91 | 1.6591 | 1 | 0.81376 | 0.089504 | 1 | 1 | 0.026316 |
| 223 | RNA transport | 169 | 3.0811 | 2 | 0.8174 | 0.087564 | 1 | 1 | 0.074766 |
| 224 | Protein processing in endoplasmic reticulum | 170 | 3.0994 | 2 | 0.81996 | 0.086207 | 1 | 1 | 0.009434 |
| 225 | Hematopoietic cell lineage | 94 | 1.7138 | 1 | 0.82384 | 0.084159 | 1 | 1 | 0 |
| 226 | Cushing syndrome | 172 | 3.1358 | 2 | 0.82498 | 0.083557 | 1 | 1 | 0 |
| 227 | mRNA surveillance pathway | 95 | 1.732 | 1 | 0.82707 | 0.082456 | 1 | 1 | 0.053571 |
| 228 | Insulin secretion | 98 | 1.7867 | 1 | 0.83643 | 0.077569 | 1 | 1 | 0 |
| 229 | cGMP-PKG signaling pathway | 183 | 3.3364 | 2 | 0.85041 | 0.070373 | 1 | 1 | 0.012195 |
| 230 | Viral protein interaction with cytokine and cytokine receptor | 103 | 1.8778 | 1 | 0.85093 | 0.070109 | 1 | 1 | 0.013699 |
| 231 | Hepatocellular carcinoma | 186 | 3.3911 | 2 | 0.85674 | 0.067152 | 1 | 1 | 0.016949 |
| 232 | Melanogenesis | 106 | 1.9325 | 1 | 0.859 | 0.066007 | 1 | 1 | 0.022727 |
| 233 | T cell receptor signaling pathway | 107 | 1.9508 | 1 | 0.86159 | 0.064698 | 1 | 1 | 0.014085 |
| 234 | Circadian entrainment | 107 | 1.9508 | 1 | 0.86159 | 0.064698 | 1 | 1 | 0.068966 |
| 235 | Chagas disease (American trypanosomiasis) | 108 | 1.969 | 1 | 0.86414 | 0.063416 | 1 | 1 | 0.041667 |
| 236 | Cellular senescence | 190 | 3.464 | 2 | 0.8648 | 0.063086 | 1 | 1 | 0.087719 |
| 237 | Toxoplasmosis | 111 | 2.0237 | 1 | 0.8715 | 0.059732 | 1 | 1 | 0.031746 |
| 238 | Tuberculosis | 195 | 3.5552 | 2 | 0.87429 | 0.058345 | 1 | 1 | 0.022059 |
| 239 | Huntington disease | 196 | 3.5734 | 2 | 0.87611 | 0.05744 | 1 | 1 | 0.029412 |
| 240 | Ribosome biogenesis in eukaryotes | 116 | 2.1149 | 1 | 0.8829 | 0.05409 | 1 | 1 | 0 |
| 241 | Focal adhesion | 201 | 3.6645 | 2 | 0.88487 | 0.053119 | 1 | 1 | 0.064516 |
| 242 | Calcium signaling pathway | 202 | 3.6828 | 2 | 0.88655 | 0.052295 | 1 | 1 | 0.029851 |
| 243 | Chemokine signaling pathway | 203 | 3.701 | 2 | 0.88821 | 0.051483 | 1 | 1 | 0.125 |
| 244 | Leukocyte transendothelial migration | 119 | 2.1696 | 1 | 0.88925 | 0.050978 | 1 | 1 | 0.010989 |
| 245 | Growth hormone synthesis, secretion and action | 120 | 2.1878 | 1 | 0.89129 | 0.049983 | 1 | 1 | 0.063492 |
| 246 | Inositol phosphate metabolism | 120 | 2.1878 | 1 | 0.89129 | 0.049983 | 1 | 1 | 0.094118 |
| 247 | Natural killer cell mediated cytotoxicity | 121 | 2.206 | 1 | 0.89329 | 0.049008 | 1 | 1 | 0.051546 |
| 248 | Pancreatic secretion | 123 | 2.2425 | 1 | 0.89718 | 0.047119 | 1 | 1 | 0 |
| 249 | Phosphatidylinositol signaling system | 127 | 2.3154 | 1 | 0.90455 | 0.043566 | 1 | 1 | 0.27273 |
| 250 | Thyroid hormone signaling pathway | 129 | 2.3519 | 1 | 0.90804 | 0.041896 | 1 | 1 | 0.037736 |
| 251 | Cytokine-cytokine receptor interaction | 296 | 5.3965 | 3 | 0.90979 | 0.041057 | 1 | 1 | 0.015 |
| 252 | Spliceosome | 132 | 2.4066 | 1 | 0.91303 | 0.039516 | 1 | 1 | 0 |
| 253 | Signaling pathways regulating pluripotency of stem cells | 138 | 2.516 | 1 | 0.92222 | 0.035167 | 1 | 1 | 0.030612 |
| 254 | Viral carcinogenesis | 231 | 4.2115 | 2 | 0.92647 | 0.033168 | 1 | 1 | 0 |
| 255 | Epstein-Barr virus infection | 232 | 4.2297 | 2 | 0.92758 | 0.032649 | 1 | 1 | 0.02069 |
| 256 | Measles | 145 | 2.6436 | 1 | 0.93172 | 0.030714 | 1 | 1 | 0.022472 |
| 257 | Dopaminergic synapse | 146 | 2.6618 | 1 | 0.93298 | 0.030127 | 1 | 1 | 0 |
| 258 | Apelin signaling pathway | 146 | 2.6618 | 1 | 0.93298 | 0.030127 | 1 | 1 | 0.04 |
| 259 | Human immunodeficiency virus 1 infection | 243 | 4.4303 | 2 | 0.93877 | 0.027442 | 1 | 1 | 0.037313 |
| 260 | Gastric cancer | 154 | 2.8077 | 1 | 0.94226 | 0.025828 | 1 | 1 | 0.029126 |
| 261 | Hepatitis C | 162 | 2.9535 | 1 | 0.95026 | 0.022156 | 1 | 1 | 0.020619 |
| 262 | Adrenergic signaling in cardiomyocytes | 162 | 2.9535 | 1 | 0.95026 | 0.022156 | 1 | 1 | 0.028169 |
| 263 | Oxytocin signaling pathway | 165 | 3.0082 | 1 | 0.95297 | 0.020921 | 1 | 1 | 0.013158 |
| 264 | Alzheimer disease | 180 | 3.2817 | 1 | 0.96446 | 0.015717 | 1 | 1 | 0 |
| 265 | Herpes simplex virus 1 infection | 439 | 8.0036 | 2 | 0.99748 | 0.001098 | 1 | 1 | 0.030303 |
| 266 | Olfactory transduction | 1141 | 20.802 | 1 | 1 | 1.14E-10 | 1 | 1 | 0 |